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Novel regulators of liver development and metabolism 
 
Abstract 
 
Chronic liver diseases such as non-alcoholic fatty liver disease and alcoholic liver disease 
are significant health concerns worldwide. Despite knowledge of disease features and 
environmental causes, we lack understanding of the genetic factors and molecular mechanisms 
that can be targeted for liver disease therapeutics. Many of these factors are also essential during 
embryonic development and organogenesis. Here, we use liver development in zebrafish as a 
model and paradigm for the discovery of regulators impacting liver disease pathogenesis. A 
chemical screen in zebrafish identified the endocannabinoid (EC) signaling pathway as a 
regulator of liver development. This pathway was previously implicated in animal models of 
chronic liver disease, but little was known about its role in development. We generated 
cannabinoid receptor mutant zebrafish using genome editing and show that EC signaling is 
required for hepatic maturation and outgrowth, but not earlier milestones such as hepatic 
specification. Mutant zebrafish also exhibited defects in lipid processing, and we found that 
methionine metabolism, involving sterol regulatory element binding proteins (SREBPs), is an 
integral mediator in this process. In a separate study, we used zebrafish to functionally annotate a 
panel of candidate genes identified by a genome-wide association study (GWAS) for elevated 
liver plasma enzymes, which are used as a clinical liver disease marker. We prioritized GWAS 
candidates for morpholino knockdown in zebrafish and discovered effects on hepatic progenitor 
and hepatocyte development as well as differences in susceptibility to metabolic and toxic injury. 
Our approach can be applied to other GWAS data sets to rapidly assess additional characteristics 
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during zebrafish development. The work presented here gives valuable insight into how 
regulators of hepatogenesis also have roles in metabolism and disease.   
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Table of Contents 
Acknowledgements ...................................................................................................................... vi!
Chapter 1: Introduction ............................................................................................................... 1!
Chronic liver disease ................................................................................................................... 2!
Zebrafish as a model organism ................................................................................................... 8!
Liver development in mammals and zebrafish ......................................................................... 10!
The endocannabinoid signaling pathway .................................................................................. 16!
Endocannabinoids and liver disease ......................................................................................... 19!
Summary ................................................................................................................................... 22!
References ................................................................................................................................. 26!
Chapter 2: Cannabinoid receptors regulate hepatic differentiation and metabolism during 
development ................................................................................................................................. 33!
Abstract ..................................................................................................................................... 35!
Introduction ............................................................................................................................... 36!
Results ....................................................................................................................................... 37!
Discussion ................................................................................................................................. 63!
Materials and Methods .............................................................................................................. 67!
References ................................................................................................................................. 72!
Chapter 3: Functional validation of GWAS gene candidates for abnormal liver function 
during zebrafish liver development ........................................................................................... 77!
Abstract ..................................................................................................................................... 79!
Introduction ............................................................................................................................... 80!
Results ....................................................................................................................................... 82!
Discussion ................................................................................................................................. 99!
Materials and Methods ............................................................................................................ 104!
Translational Impact ............................................................................................................... 105!
References ............................................................................................................................... 107!
Chapter 4: Discussion ............................................................................................................... 110!
Summary ................................................................................................................................. 111!
Future Directions and Conclusions ......................................................................................... 112!
References ............................................................................................................................... 118!
Appendices ................................................................................................................................. 119!
Appendix 1: Chapter 2 Supplemental Data ............................................................................ 119!
Appendix 2: Chapter 2 Ongoing experiments ........................................................................ 134!
Appendix 3: Chapter 3 Supplemental Data ............................................................................ 144!
 
 
  vi 
Acknowledgements 
 
The PhD dissertation is one of the few single-author works remaining in science and the 
sole authorship of this manuscript belies the immense contributions of many individuals and 
organizations throughout my graduate education. The help I received spanned everything from 
experimental instruction to scientific and personal mentoring to daily encouragement and 
inspiration. I am sincerely grateful for the contributions of many: 
My PhD advisor, Wolfram Goessling, has been a great educator, scientific leader, and the 
ultimate enthusiastic presence throughout my graduate education. He has generously guided my 
scientific progress and set a crucial example of how to overcome obstacles while still succeeding 
in his career. From Wolfram, I learned how to formulate a compelling scientific story, greatly 
improved my ability to write convincingly, and give memorable scientific presentations. Every 
time we meet, I am inspired by Wolfram’s passion for scientific research and being a PI.  
The members of the Goessling Lab have been excellent colleagues, scientific 
collaborators, educators, and friends. I greatly appreciate the patience, knowledge, skill, and 
camaraderie exhibited by present and past members of the Goessling Lab: Maija Garnaas, Gal 
Chataruntabut, Katie Lee Hwang, Olivia Weeks, Kristen Alexa, Chad Walesky, Andy Cox, 
Sahar Nissim, Hongchao Zhou, AJ Kim, John Hedgepeth, Allison Tsomides, Steph Schatzman-
Bone, Marcelle Goggins, Jiyun Chang, Diane Saunders, Julia Wucherpfennig, and Rachel Lucier.  
I would like to thank the members of my Dissertation Advisory Committee: Ramesh 
Shivdasani, Caroline Burns, and David Cohen for their advice and scientific input throughout my 
graduate career. I would also like to thank my Dissertation Exam Committee: Caroline Burns, 
Richard Maas, Calum MacRae, and Amy Walker for taking the time to critically read my 
  vii 
dissertation. I am grateful for the effort these committee members have taken to encourage my 
progress and support the research endeavors of graduate students. 
The Biological and Biomedical Sciences (BBS) PhD Program has been a welcoming 
academic home and a true social community. I have been fortunate to take advantage of the 
many resources and scientific opportunities within BBS and at Harvard. I am thoroughly 
thankful for the student-centered, flexible, and progressive environment created by the BBS 
program heads and the BBS Office, specifically Kate Hodgins, Maria Bollinger, Danny 
Gonzalez, and Tucker Hodgins. They are an ever-present source of practical advice and helpful 
encouragement and are indispensible to organizing the programming that introduced me to 
lifelong friends and allowed me to become an involved member of the BBS community. 
 The Leder Human Biology program has been a wonderful educational and paracurricular 
network for exploring aspects of the research enterprise I wouldn’t otherwise experience in the 
lab. I appreciate the mentorship of professors Connie Cepko and Thomas Michel, who are my 
models for spearheading a compelling educational program and promoting the ideas of students. 
I also thank the Developmental and Regenerative Biology program for being a resource and 
community for students interested in developmental biology.  
Science in the News has been an inspiring organization of peers similarly passionate 
about science communication. I thank my fellow lecturers and coordinators for their confidence 
in my abilities and including me in their effective public education endeavors. I have learned so 
much from my talented, articulate, and creative peers regarding leadership, public speaking, and 
education that I will continue to use throughout my career.  
 My graduate student friendships have been a necessary and welcome source of 
entertainment, reassurance, and motivation. We have cheered each other’s successes through the 
  viii 
years, learned from one another, and embarked on many adventures together. Being around this 
group of multi-talented brilliant scientists and caring individuals has been incredibly inspiring. I 
thank: Ryan Lee, Matt Owen, Peter Wang, Ben Morris, Ryan Kuzmickas, Leah Silverstein, Kat 
Pak, Lauren Barclay, Diane Shao, Natalie German, Katherine Helming, Amy Emerman, Dan 
Dwyer, Jamie Schafer, Le Cong, and Steph Guerra. In particular, I thank Clare Malone, Amy 
Rohlfing, and Adrianna San Roman, not only for their deep understanding of our unique 
graduate school experiences, but also for being my mentors, feminist icons, and role models 
when I needed them most.  An acknowledgement of my friends wouldn’t be complete without 
crediting Penguin Pizza, where we were “upgraded regulars” thanks to our frequent presence. 
Thank you to Niall, Andrew, and Christina for being there for us on good days and on bad days. 
 My dear friends outside of graduate school, many of whom I have known for 10 or even 
20 years, have been wonderfully supportive and thoughtful, always interested in my progress, 
and eager to listen. I am thoroughly touched by their generosity of time and energy, and proud of 
the brilliant and talented individuals they have become. I cherish the shared history and mutual 
understanding of my childhood best friends Sandy Zhao and Mandy Zhao, and it has been a 
sincere joy that young adulthood has reunited us in New England. My beloved friends from Penn 
State University have made the greatest effort to stay involved in one another’s lives: Mike 
McShane, Matt Popek, Leah Ruth, Janelle Maloch, and Mike Maloch. I would like to highlight 
the friendship of Matt Borgia, who reminds me to maximize the fun in life, and Becky Lantz, the 
best best friend. Becky has always gone above and beyond for all the major milestones in my life. 
Her initiative, kindness, and generosity have brought me much joy and comfort for the past 10 
years. I would like to thank the institution that brought all these amazing individuals together in 
  ix 
friendship, Penn State University, where I gained the confidence and the abilities to pursue 
graduate education and a career in science.  
Penn State will always be synonymous with family: it is also where my parents worked, 
where my in-laws attended school, and where I met my husband. My husband, Jonathan Lichkus, 
has been the ultimate partner in this journey. There are no words to express my appreciation for 
his kindness, patience, and love. He has made all of my personal and career priorities his own, 
and despite his own demanding career, never lacks energy for excitement and adventure. It has 
been my great joy to see him achieve his own career goals and be my daily example of someone 
who gives 200% not only in his job, but also in his relationships. With my marriage, I had the 
great fortune of gaining a bonus set of parents, and for the first time in my life, siblings. I thank 
Beverly, Andrew, Richard, and Ashley Lichkus, and Ryan Raybuck for never treating me as 
anything less than family.  
I dedicate this work to my parents, Qingping and Zhaowei Liu, who are the source of all 
my positive attributes. From childhood, they have supported my interests and devoted 
themselves to my happiness and success to provide an upbringing very different from their own. 
My parents gave me the opportunity to choose my future, which is a luxury many of us take for 
granted. The more I grow older, the more I realize how my parents really did know best. Thank 
you for always being there for me. I also thank my grandparents, and numerous aunts, uncles, 
and cousins in China, whose support and thoughtfulness despite my inability to visit often have 
been motivating. My family, whether a Liu, or a Lichkus, were the ones most impacted by the 
sacrifices and challenges of graduate school. I am ever grateful for their love and understanding 
and I share the happiness of my successes with them.  
  1 
Chapter 1: Introduction 
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Chronic liver disease 
 
Chronic liver diseases such as non-alcoholic fatty liver disease and alcoholic liver disease 
(NAFLD and ALD, respectively) contribute to significant morbidity and mortality around the 
world. NAFLD currently affects up to 38% of the U.S. population (Anstee and Day, 2013) and 
20-30% of European, Middle Eastern, and East Asian populations. Prevalence of NAFLD is 
projected to increase as more people worldwide adopt a Western-style diet and lifestyle, which 
contributes to obesity (Loomba and Sanyal, 2013). ALD is estimated to account for 10% of 
disability-adjusted life-years in developed countries, causes a greater number of liver disease 
deaths in the US than hepatitis C, and is second only to viral hepatitis as the major cause of liver 
transplantation (Altamirano and Bataller, 2011). ALD and NAFLD follow a similar disease 
progression despite their different causes: early stages of chronic liver disease include hepatic 
steatosis or fatty accumulation in the liver, followed by hepatitis or inflammation. Prolonged 
exposure leads to liver cell death and scar tissue formation called cirrhosis, which is irreversible, 
and these disease states predispose to cancers such as hepatocellular carcinoma (HCC). Liver 
transplantation can be curative but organs are scarce and patients are required to undergo lifelong 
immunosuppression. Unfortunately, no effective drug options for chronic liver disease currently 
exist, and early diagnosis is difficult due to lack of prognostic symptoms and a limited 
understanding of disease mechanisms. The goal of our lab and others is to characterize the 
molecular mechanisms of liver disease pathogenesis to reveal processes that can be targeted for 
novel therapeutics. 
The liver is the largest human internal organ and its essential metabolic functions include 
maintenance of glucose homeostasis, detoxification of drugs, and cholesterol/fat synthesis, which 
all exhibit compromised function during disease. The liver also produces essential factors, such 
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as bile to digest lipids and coagulation proteins to clot blood (Si-Tayeb et al., 2010; Zorn, 2008). 
Parenchymal cells called hepatocytes, which comprise approximately 70-80% of the liver, 
perform most of these functions (Figure 1-1). Mammalian liver cellular architecture consists of 
hepatocytes arranged in a hexagonal lobule with blood-filled sinusoids surrounded by the “portal 
triad.” The portal triad consists of the bile duct, portal vein, and hepatic artery that supply blood 
to the liver, with blood exiting through the central vein at center of the lobule (Si-Tayeb et al., 
2010). Secretion of bile occurs from the apical face of the hepatocytes adjacent to bile canaliculi 
and into the intrahepatic and extrahepatic bile ducts and gallbladder (Zorn, 2008). Non-
parenchymal liver cells include the Kupffer cells, which are liver-resident macrophages, and the 
hepatic stellate cells (HSC), which are perisinusoidal cells that mediate liver fibrosis. In response 
to liver injury, HSCs transdifferentiate from vitamin A storage cells into fibrogenic 
myofibroblast cells that secrete cytokines, reactive oxygen species (ROS), and inflammatory 
mediators. In adult mammals, the liver can regenerate up to 70% of its mass, primarily through 
proliferation of differentiated hepatocytes (Si-Tayeb et al., 2010). 
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Figure 1-1. Mammalian liver morphology and cellular architecture (Zorn, 2008) 
A) Digestive organ morphology including the liver (red), gall bladder and bile ducts (green), and 
stomach (yellow).  
B) Liver cellular architecture showing hepatocytes emanating from a central vein and flanked by 
the portal triad of a bile duct, portal vein, and hepatic artery. 
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Hepatic steatosis, also known as fatty liver, refers to lipid accumulation inside 
hepatocytes. Although steatosis by itself is reversible, continued fatty deposition leads to 
inflammation and irreversible fibrosis, which alters liver structure and function (Figure 1-2). 
Steatosis is a defining feature of both ALD and NAFLD. NAFLD is the liver manifestation of 
obesity and the metabolic syndrome, which is strongly correlated with features such as insulin 
resistance, glucose intolerance, and type 2 diabetes (Anstee and Day, 2013). As obesity 
continues to impact a growing proportion of the population, NAFLD rates have increased, with 
67% of overweight and 94% of obese individuals affected (Anstee and Day, 2013). ALD patients 
also have steatosis, which is instead triggered by excess alcohol consumption that initiates pro-
lipogenic pathways in the liver. ALD patients are at high risk for cirrhosis, with up to 40% of 
patients developing liver fibrosis and up to 20% developing cirrhosis (Altamirano and Bataller, 
2011). 
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Figure 1-2. Schematic of liver disease progression  
Injury to the liver due to nutritional, drug, or alcohol sources can cause steatosis, steatohepatitis 
or liver inflammation, and acute liver toxicity. Continued exposure to an injury state can result in 
scar tissue formation (cirrhosis), which impairs proper liver function and predisposes to 
hepatocellular carcinoma (Adapted from Cohen et al 2007). 
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It is commonly understood that while a first “hit”, steatosis, disrupts lipid homeostasis in 
the liver during NAFLD, a second “hit” such as inflammatory cytokine release, oxidative, or 
endoplasmic reticulum (ER) stress is also required for hepatic steatosis to progress to an 
inflammatory cirrhotic state (Asaoka et al., 2013; Day and James, 1998; Koteish and Mae Diehl, 
2002) (Figure 1-2). An imbalance of gut microbiota resulting from overnutrition may also lead to 
the presence of bacterial products in the portal circulation, which can act to trigger innate 
immune responses (Hebbard and George, 2011; Mehal, 2013). Cirrhosis is characterized by 
fibrosis, proliferative nodules, hepatocyte death, and vascular reorganization, which may lead to 
liver failure that currently can only be treated by liver transplantation. The combination of 
increased free fatty acids, inflammatory response, ROS, and autophagy can cooperate to damage 
hepatocytes, initiate scar tissue formation, even promote malignant transformation (VanSaun et 
al., 2009).  
The most common form of liver cancer, hepatocellular carcinoma (HCC), is the fourth 
deadliest cancer, with a relative 3-year survival rate of 17% (El-Serag, 2007). The vast majority 
(up to 80%) of HCC cases arise from cirrhosis, and NAFLD contributes to 58% of HCC patients 
(Anstee et al., 2013). The estimated stabilization of HCC incidence from viral hepatitis is 
expected to be superseded by the increase of HCC from NAFLD (El-Serag, 2007). Current 
research into this disease progression from simple steatosis to cirrhosis and malignant 
transformation seeks to identify tractable drug targets (Wree et al., 2013). 
The genetic factors mediating NAFLD and ALD disease progression are not well 
understood; however, studies of families and twins, and across ethnicities imply a strong genetic 
component (Altamirano and Bataller, 2011; Anstee and Day, 2013). Identifying the molecular 
pathways that cause or modulate disease progression can distinguish the populations at greatest 
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risk and lead to novel therapies in this area of great clinical need. Animal models of liver disease 
have proven useful for elucidating gene functions and for drug discovery. Aspects of chronic 
liver diseases can be modeled in mice and zebrafish using specialized diets such as high fat diet, 
methionine/choline deficient diet, and administration of ethanol or hepatotoxins such as 
thioacetamide (Altamirano and Bataller, 2011; Amali et al., 2006; Rekha et al., 2008). Genetic 
models exhibiting features of hepatic steatosis also exist, including the foie gras (Sadler et al., 
2005) and dtp+/- mutant zebrafish, the leptin deficient ob/ob mice, or other mice lacking genes 
important for carbohydrate and lipid metabolism or the inflammatory response  (Anstee and 
Goldin, 2006; Hebbard and George, 2011; Koteish and Mae Diehl, 2002). 
 
Zebrafish as a model organism 
 
Determination of disease mechanisms requires an experimental system that closely 
recapitulates the interaction between complex tissues and environments. Furthermore, drug 
discovery can be made more informative and applicable to humans when using in vivo animal 
models rather than isolated cell populations. The zebrafish (Danio rerio) has been an important 
vertebrate model for elucidating the mechanisms of organogenesis and disease pathogenesis. 
Developmental and physiological programs in zebrafish and mammals are highly conserved, 
with 70% similarity (Howe et al., 2013) between zebrafish and humans. Unlike mice, zebrafish 
breeding strains are outbred populations, which allow for assessment of phenotypic variation 
across defined populations and relevance to human genetic variation. Examples of human 
diseases that can be modeled in zebrafish include developmental defects, liver disease, infectious 
disease, hematopoietic malignancies, and solid tumors (Berghmans et al., 2005; Haramis et al., 
2006; Lieschke and Currie, 2007; Patton et al., 2005; Tobin et al., 2010).  
  9 
Several experimental features make zebrafish an attractive model organism. Hundreds of 
embryos can arise from a single mating per week, and these embryos are optically clear, leading 
to efficient analysis of large numbers simultaneously. Embryogenesis proceeds on a faster time 
scale in zebrafish compared to mammals. Because embryonic development occurs externally, 
visualization of developmental milestones can occur in vivo, and use of transgenic fluorescent 
reporters have led to many insights when employing live visualization of organs or even 
individual cells. Furthermore, transgenic reporters and genome editing technology such as zinc 
finger nucleases (ZFN), transcription activator like effector nucleases (TALEN), and the 
clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system can be applied 
to the analysis of normal and aberrant states in zebrafish.  
The first large-scale genetic screens using vertebrates were conducted with zebrafish and 
yielded a variety of mutants to inform essential developmental processes such as germ layer 
specification and organogenesis (Driever et al., 1996; Haffter et al., 1996). Since then, zebrafish 
have proven to be a powerful vertebrate model for both genetic and chemical screening, which 
have emerged as effective methods to generate mutants, discover novel pathways, and test drug 
efficacy (Lieschke and Currie, 2007; Patton and Zon, 2001). Beyond screening for 
developmental defects, newer technologies allow for screening to include fluorescent reporters 
and modulation of disease phenotypes.   
The zebrafish liver performs the same functions as the mammalian liver and is subject to 
similar injury induction procedures that can be modified experimentally using chemical and 
genetic tools. An advantage of modeling liver disease in zebrafish is that injury can be studied in 
both the larval and adult stages. Larval studies allow for high-throughput testing and rapid 
experiment times. Alcoholic steatosis, acetaminophen-induced liver toxicity, and diet-induced 
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steatosis are all injury conditions that can be modeled in zebrafish larvae (Farber et al., 2012; 
North et al., 2010; Passeri et al., 2009; Tainaka et al., 2011). Previous studies have also 
established partial hepatectomy in zebrafish as a method to discover and assess regulators of 
adult liver regeneration (Goessling et al., 2008; Sadler et al., 2007).  
As zebrafish continue to gain prominence as a model organism for studying 
developmental processes and for modeling injury and disease, many laboratories have developed 
experimental tools for the detection and analysis of specific liver cell types. The cell types 
important for mammalian liver function and injury response are also conserved in zebrafish. The 
Tg(fabp10a:GFP) hepatocyte reporter line has long been used for visualizing liver size and 
hepatic damage over time (Her et al., 2003). More recently, hand2, which becomes upregulated 
during liver injury, has been identified as the zebrafish hepatic stellate cell marker (Yin et al., 
2012). Additionally, fluorescent reporter lines are also available for studying liver endothelial 
cells (Sakaguchi et al., 2008) and macrophages have been found in the zebrafish liver (Wittamer 
et al., 2011), but their characterization as bona fide Kupffer cells has not been established. 
Zebrafish biliary development occurs in parallel with hepatocyte expansion and liver outgrowth. 
The 2F11 marker and ck19 transgenic reporter (Crosnier, 2005; Wilkins et al., 2014) are tools to 
visualize biliary epithelial cells, while exposure to digestible fluorophores such as PED6 and 
BODIPY-C5 (Carten et al., 2011; Farber et al., 2001) allow for in vivo analysis of gall bladder 
structure and function, lipase activity, and lipid metabolism in the biliary system.  
Liver development in mammals and zebrafish 
 
Liver disease pathogenesis involves proliferation and recapitulation of genetic pathways 
normally limited to liver development. Many pathways necessary for organogenesis are 
frequently disrupted during disease, and this relationship is conserved in zebrafish. For example, 
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Wnt signaling, as described below, is essential for hepatic specification and outgrowth. Its 
requirement in specific cell types and at specific times is integral for proper liver formation 
(Goessling et al., 2008). This pathway is frequently mutated or aberrantly expressed in human 
cancers such as liver and colorectal cancers. Therefore, knowledge of the spatial and temporal 
actions of important developmental regulators is not only critical for describing key milestones 
in organ formation, but also provide therapeutic targets for adult diseases when these regulators 
become perturbed. Another example is prostaglandin E2, which was originally implicated in 
zebrafish as an important regulator of hematopoietic stem cell proliferation. This molecule is 
now in human clinical trials as a potential drug for improving the outcome of umbilical cord 
blood transplantation (Goessling et al., 2011; North et al., 2007). Additionally, leflunomide is a 
drug previously approved for rheumatoid arthritis and was discovered in a zebrafish screen for 
inhibitors of neural crest development. This drug was found to be effective in zebrafish and 
murine models of melanoma, which is a cancer of the neural crest lineage, and its effectiveness is 
now being tested in clinical trials to treat patients with advanced melanoma (White et al., 2011).  
The liver derives from the endoderm, which gives rise to the gastrointestinal and 
respiratory tracts in vertebrates. During gastrulation in mice, the transforming growth factor 
(TGF)-β signaling molecule Nodal functions by embryonic day 7 (e7) to delineate between 
endodermal and mesodermal fates in a concentration-dependent manner, with higher 
concentrations inducing endodermal fate (Zorn, 2008). Sox17 and FoxA1-3 act downstream of 
Nodal and are essential for endoderm induction (Fukuda and Kikuchi, 2005). During early 
somitogenesis, FGF and Wnt signaling gradients pattern the endoderm along the anterior-
posterior axis, with repression of Wnt leading to formation of the foregut, which is the future site 
of the liver (Zorn, 2008). Hepatic induction is initiated from FGF and BMP signals in the 
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mesoderm, while transcription factors Hhex, Prox1, and Gata4,6 are required for hepatoblast 
specification (Si-Tayeb et al., 2010). In contrast to early somitogenesis when Wnt represses liver 
development, Wnt signaling during liver bud outgrowth enhances hepatocyte proliferation and 
differentiation (Zorn, 2008). Hepatoblasts have bipotential characteristics, with those located 
near portal veins differentiating into biliary epithelial cells via Wnt, TGFβ, and Notch signaling 
while most other hepatoblasts take on hepatocyte fate (Zorn, 2008). Mouse liver development 
proceeds throughout embryonic development in utero and hepatic maturation continues after 
birth (Figure 1-3). 
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Figure 1-3. Mouse liver development 
Mouse liver development begins with endoderm formation at embryonic day 7 (e7), followed by 
hepatic specification in the foregut endoderm (fg) and development of the liver diverticulum (ld) 
by e9. Hepatocyte differentiation and liver maturation continues up to birth and postnatally (Zorn, 
2008). 
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This process is conserved in vertebrates, including zebrafish. The endoderm is 
distinguished in zebrafish through the upstream action of Nodal signals to activate gata5/fau, cas, 
and subsequently sox17, which is expressed beginning at gastrulation (Alexander and Stainier, 
1999; Stainier, 2002). By 24 hours post fertilization (hpf), most organ systems are specified in 
zebrafish. Specifically, hepatoblasts, or hepatic progenitors, are specified in the anterior foregut 
endoderm at 22 hpf and can be identified by the expression of hhex and prox1 (Shin et al., 2007) 
(Figure 1-4). By 48 hpf, hepatocyte and biliary differentiation begin, which can be visualized by 
the expression of fabp10a, a marker of differentiated hepatocytes (Her et al., 2003). The liver 
bud can be detected on the left side of the dorsal midline, over the yolk. Similar to mice, Fgf, 
Bmp, and Wnt signals drive hepatogenesis in zebrafish. Wnt induction early in development acts 
to inhibit liver formation, while later Wnt induction acts to promote hepatic differentiation and 
proliferation (Chu and Sadler, 2009; Goessling et al., 2008). Furthermore, Notch signaling plays 
an important role in specifying biliary cells (Lorent, 2004). 
The enzymatic and bile excretion functions of the liver are fully functional by 5 days post 
fertilization (dpf), concurrent with exhaustion of yolk nutrition and transition to feeding on 
outside energy sources. The growth of the liver is also supported by, but not dependent on 
expansion of endothelial cell population to form the liver vasculature (Chu and Sadler, 2009; 
Sakaguchi et al., 2008). Importantly, embryonic hematopoiesis does not occur in the liver, unlike 
in mammals, so analysis of liver defects can occur without danger of embryonic lethality due to 
anemia. Although many of the pathways governing early liver formation have been characterized, 
our understanding of liver associated processes such as embryonic energy utilization is still 
lacking.   
 
  15 
 
 
Figure 1-4. Zebrafish liver development 
Zebrafish liver development begins with hepatic specification via Fgf, Bmp, and Wnt signals by 
24 hours post fertilization (hpf) from the endoderm (purple). Hepatic progenitors can be 
identified by the expression of hhex and prox1, and the liver (green) begins to differentiate and 
bud at 48 hpf, with hepatocyte proliferation and hepatic outgrowth proceeding from 72 hpf 
onward. Image courtesy of Diane Saunders.  
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The endocannabinoid signaling pathway  
  
The endocannabinoid (EC) signaling pathway has known roles in liver disease and also 
influences motor function, appetite, energy balance, cell fate, and immune/inflammatory 
responses (Caraceni et al., 2009). However, this pathway has no previously established role in 
liver development. Endocannabinoids are endogenous arachidonic-acid derived lipid signaling 
molecules that act through the cannabinoid receptors CB1 and CB2, which are encoded by the 
cnr1 and cnr2 genes, respectively (Matsuda et al., 1990; Munro et al., 1993). The endogenous 
ligands for CB1 and CB2 are 2-arachidonoyglycerol (2-AG) (Sugiura et al., 1995) and 
anandamide (AEA) (Felder et al., 1993), which are degraded by monoacylglycerol lipase and 
fatty acid amid hydrolase, respectively (Silvestri and Di Marzo, 2013). The metabolic pathways 
involving EC synthesis and degradation have been well characterized, although there may be 
additional EC molecules that have not been discovered. The primary psychoactive ingredient in 
marijuana, Δ9-tetrahydrocannabinol (THC), shows structural similarity to AEA and 2-AG and 
acts at CB1 and CB2 to produce its cognitive and sedative effects (Guzmán, 2003).  
CB1 and CB2 are G-protein coupled receptors (GPCR) that inhibit adenylyl cyclase and 
decrease cyclic AMP levels while stimulating MAP kinase. Binding to receptors also alters 
calcium and potassium channel activity, which leads to activation of the ERK, JNK, or 
PI3K/AKT downstream pathways to control cell fate (Figure 1-5) (Felder et al., 1993; McAllister 
and Glass, 2002; Pagotto et al., 2006). CB1 and CB2 can mediate distinct downstream effects: 
CB1 couples to K+ and Ca++ channels to inhibit the release of neurotransmitters whereas CB2 
does not (Caulfield and Brown, 1992; McAllister and Glass, 2002). Endocannabinoid signaling 
also regulates sphingolipid metabolism via sphingomyelin breakdown and increasing levels of 
ceramide (Figure 1-5). In the central nervous system, EC signaling modulates appetite and 
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feeding response via retrograde signaling at synapses to inhibit neurotransmitter release (Silvestri 
and Di Marzo, 2013). The role of cannabinoids in cancer is unclear: in cancer cell lines but not in 
untransformed cell lines, cannabinoids have been found to induce apoptosis, initiate cell-cycle 
arrest, or inhibit angiogenesis. Interestingly, in many cases, this occurs in tumors where receptor 
expression positively correlates with tumor aggressiveness, and inhibition of signaling through 
CB1 using antagonists can slow tumor growth in several in vitro and in vivo cancer models 
(Guzmán, 2003; Pisanti et al., 2013).  
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Figure 1-5. Endocannabinoid signaling and activation of downstream pathways  
After binding to their receptors, cannabinoids can mediate many downstream pathways to impact 
cell fate and cellular metabolism, including inhibition of the adenylyl cyclase (AC)-cyclic AMP 
(cAMP)-protein kinase A (PKA) pathway, inhibition of voltage sensitive calcium channels, 
activation of the PI3K/AKT signaling, activation of MAP-kinase cascades such as ERK, JNK, 
p38, and production of ceramide through sphingomyelinase (SMase) to promote apoptosis.  
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At the tissue level, CB1 is the most abundant GPCR in the central nervous system (CNS) 
but is also expressed in the peripheral nervous system (PNS) and peripheral organs. CB1 is first 
expressed in zebrafish at the 3-somite stage (Migliarini and Carnevali, 2009) and exposure to 
AEA induces expression of CB1 (Migliarini and Carnevali, 2008). In mammals, CB2 is 
primarily expressed in immune cells (Atwood and Mackie, 2010), and in zebrafish, CB2 is 
expressed in the adult heart, intestine, spleen, and portions of the CNS (Rodriguez-Martin et al., 
2007). There are many chemical modulators of cannabinoid receptor function that have been 
used in research and as drugs. THC and its derivatives have been approved for treatment of 
nausea and vomiting in cancer patients undergoing chemotherapy, and have the effect of 
increasing appetite (Guzmán, 2003). There are many unanswered questions in the EC signaling 
field, such as how this pathway functions during early development and how signaling through 
cannabinoid receptors determines cell fate in different cell types.    
Endocannabinoids and liver disease 
 
Experiments using chemical modulators and conditional mouse mutants have shown that 
in addition to CNS effects, the EC system has independent metabolic and injury response 
functions in peripheral tissues such as the gut and the liver. In mammals, CB1 and CB2 are 
weakly expressed in the liver under normal conditions (Mallat and Lotersztajn, 2008), but are 
upregulated during chronic liver diseases such as NAFLD, ALD, viral hepatitis, cirrhosis, and 
HCC (Caraceni et al., 2009; van der Poorten et al., 2010). CB1 activation induces de novo fatty 
acid synthesis in the liver, mediated through the central lipogenic transcription factor sterol 
regulatory element binding protein 1-C, (SREBP-1C) (Osei-Hyiaman et al., 2005b), whereas 
CB1-/- mice are resistant to diet and ethanol-induced steatosis (Jeong et al., 2008; Osei-Hyiaman 
et al., 2008). In mammals and zebrafish, CB1 activation in the liver drives SREBP-1C to 
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increase expression of fatty acid synthase, acetyl CoA carboxylase, and other enzymes that 
increase fatty deposition (Migliarini and Carnevali, 2008).  In addition to its lipogenic roles, CB1 
also regulates pro-fibrogenic pathways and is highly upregulated during fibrosis in hepatocytes 
(Osei-Hyiaman et al., 2005a) and in non-parenchymal liver cells (Teixeira-Clerc et al., 2010). 
Previously, the CB1 antagonist rimonabant was found to reduce weight and improve liver 
enzyme levels in obese and diabetic human patients (Kaser et al., 2010). Unfortunately, drug 
trials in Europe revealed increased depression and suicide risk due to rimonabant action in the 
CNS, leading to the removal of this drug from the market (Izzo and Sharkey, 2010). However, 
newly-developed peripherally-restricted CB1 drugs may circumvent this problem (Tam et al., 
2010), or alternatively, modulating the CB2 receptor may also decrease susceptibility or severity 
of metabolic liver disease. 
Whereas CB1 activation is pro-fibrogenic and favors liver disease progression, CB2 
activation inhibits disease processes by decreasing inflammation, proliferation, and oxidative 
stress (Bátkai et al., 2007; Julien et al., 2005) (Figure 1-6). CB2 is also upregulated in liver 
disease; administration of CB2 agonists results in decreased inflammation, decreased fibrosis, 
and a reduction in activated HSCs in a mouse model of cirrhosis (Muñoz-Luque et al., 2008). 
Hepatotoxin administration and partial hepatectomy in CB2-/- mice result in greater liver injury 
and delayed liver regeneration while treatment with CB2 agonists results in reduced injury and 
enhanced regeneration (Teixeira-Clerc et al., 2010). CB1 and CB2 appear to have opposing roles 
in the same disease process; however, CB1 effects may predominate in liver pathogenesis, since 
frequent marijuana users display liver fibrosis and THC acts on both receptors (Hézode et al., 
2005; Siegmund and Schwabe, 2008).  
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Figure 1-6. CB1 and CB2 functions in liver disease 
Studies using mouse models and chemicals have implicated signaling through CB1 in promoting 
liver lipogenesis and fibrosis. In contrast, signaling through CB2 may ameliorate or prevent fat 
accumulation and scar tissue formation. Cannabinoid agonists act on CB2 in liver immune cells 
and hepatic stellate cells while cannabinoid antagonists inhibit signaling through CB1 in 
hepatocytes and hepatic stellate cells to improve liver disease features.  
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Summary 
 
In the ensuing chapters, we apply two parallel experimental approaches for examining the 
intersection of liver development and disease. Chapter 2 explores the role of endocannabinoid 
signaling in hepatic maturation and analyzes the molecular and metabolic regulators of this 
pathway as the liver matures. The CB1 and CB2 receptors are expressed in liver tissue and have 
divergent roles in mediating hepatic lipogenesis and fibrogenesis. However, the role of the EC 
pathway in embryonic development, specifically liver specification and growth, is unknown. Our 
lab has successfully modeled aspects of liver injury and used zebrafish to screen for novel 
compounds and pathways that modulate liver disease (North et al., 2010). We previously 
conducted a chemical screen that spanned the endoderm specification, hepatoblast differentiation, 
and hepatocyte proliferation stages of hepatogenesis to identify novel regulators of liver 
development. We exposed the Tg(fabp10a:GFP) liver reporter line to a library of ~2600 
bioactive compounds and found that 8.7% of the compounds increased liver size and 5% 
decreased liver size (Figure 1-7). Many of the molecular pathways identified by this chemical 
screen such as retinoic acid signaling, nitric oxide signaling, and prostaglandins were found to be 
important for endoderm and hepatic formation (Cox et al., 2013; Garnaas et al., 2012; Goessling 
et al., 2009; Nissim et al., 2014; North et al., 2010). Eicosanoid modulators represented 18% of 
the hits from the screen, and five of these compounds were endogenous or exogenous 
cannabinoid agonists that all increased liver size in Tg(fabp10a:GFP) fish (Figure 1-8). This 
approach identifies a novel developmental pathway using a zebrafish model and our work in 
Chapter 2 reveals new insights into its molecular mechanisms with relevance for human liver 
physiology and disease susceptibility.  
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Figure 1-7. Schematic of chemical screen  
Tg(fabp10a:GFP) fish expressing GFP under a liver specific promoter were exposed to a library 
of 2640 chemicals from 18-72 hours post fertilization (hpf). At 72 hpf, 8.7% of the compounds 
were found to decrease liver size and 5.1% increased liver size. 
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Figure 1-8. Chemical screen hits 
Compounds from the screen that modulated liver size were grouped into common pathways, with 
vasoactive, eicosanoid, and psychiatric chemicals representing the majority of the hits. 
Eicosanoid modulators represented 18% of the compound hits, and the five cannabinoid agonists 
from the screen that all increased liver size are listed in the table at right. 
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Conversely, in Chapter 3, we undertook a different approach to identify novel regulators 
of liver development and began with a human genomic data set. We analyzed genome-wide 
association study (GWAS) data for candidates associated with elevated liver enzyme levels 
(Chambers et al., 2011). Although candidate gene studies have linked certain genetic variations 
to liver disease traits, GWAS allow for an unbiased assessment of traits in large populations to 
discover previously uncharacterized associations. Novel genetic associations often have 
previously unknown biological functions or mechanisms, necessitating extensive follow-up to 
establish biological importance. Compared to inbred rodent models, wild type zebrafish are 
outbred populations and allow for analysis of population-wide phenotypic variation that is found 
in humans. This system provides initial data for additional analysis of specific candidates, so 
resource-intensive experiments can be focused to genes most likely to have an important 
biological function.  
These two chapters represent complementary ways a vertebrate model can be used to 
study the biological and disease relevance of novel regulators. The zebrafish can play an integral 
role in the translational application of genomic data from population-based studies: discoveries 
made in humans via GWAS can be validated and interrogated in zebrafish or other model 
organisms to gain insight into biological mechanisms that can be applied back to human disease.   
  
  26 
References 
 
Alexander, J., and Stainier, D.Y. (1999). A molecular pathway leading to endoderm formation in 
zebrafish. Curr Biol 9, 1147–1157. 
Altamirano, J., and Bataller, R. (2011). Alcoholic liver disease: pathogenesis and new targets for 
therapy. Nat Rev Gastroenterol Hepatol 8, 491–501. 
Amali, A.A., Rekha, R.D., Lin, C.J.-F., Wang, W.-L., Gong, H.-Y., Her, G.-M., and Wu, J.-L. 
(2006). Thioacetamide induced liver damage in zebrafish embryo as a disease model for 
steatohepatitis. J Biomed Sci 13, 225–232. 
Anstee, Q.M., and Day, C.P. (2013). The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 10, 
645–655. 
Anstee, Q.M., and Goldin, R.D. (2006). Mouse models in non-alcoholic fatty liver disease and 
steatohepatitis research. Int J Exp Pathol 87, 1–16. 
Anstee, Q.M., Targher, G., and Day, C.P. (2013). Progression of NAFLD to diabetes mellitus, 
cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10, 330–344. 
Asaoka, Y., Terai, S., Sakaida, I., and Nishina, H. (2013). The expanding role of fish models in 
understandingnon-alcoholic fatty liver disease. Disease Models & Mechanisms. 
Atwood, B.K., and Mackie, K. (2010). CB2: a cannabinoid receptor with an identity crisis. Br J 
Pharmacol 160, 467–479. 
Bátkai, S., Osei-Hyiaman, D., Pan, H., El-Assal, O., Rajesh, M., Mukhopadhyay, P., Hong, F., 
Harvey-White, J., Jafri, A., Haskó, G., et al. (2007). Cannabinoid-2 receptor mediates protection 
against hepatic ischemia/reperfusion injury. Faseb J 21, 1788–1800. 
Berghmans, S., Murphey, R.D., Wienholds, E., Neuberg, D., Kutok, J.L., Fletcher, C.D.M., 
Morris, J.P., Liu, T.X., Schulte-Merker, S., Kanki, J.P., et al. (2005). tp53 mutant zebrafish 
develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci USA 102, 407–412. 
Caraceni, P., Domenicali, M., Giannone, F., and Bernardi, M. (2009). The role of the 
endocannabinoid system in liver diseases. Best Practice & Research Clinical Endocrinology & 
Metabolism 23, 65–77. 
Carten, J.D., Bradford, M.K., and Farber, S.A. (2011). Visualizing digestive organ morphology 
and function using differential fatty acid metabolism in live zebrafish. Dev Biol 360, 276–285. 
Caulfield, M.P., and Brown, D.A. (1992). Cannabinoid receptor agonists inhibit Ca current in 
NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106, 
231–232. 
Chambers, J.C., Zhang, W., Sehmi, J., Li, X., Wass, M.N., Van der Harst, P., Holm, H., Sanna, 
S., Kavousi, M., Baumeister, S.E., et al. (2011). Genome-wide association study identifies loci 
  27 
influencing concentrations of liver enzymes in plasma. Nat Genet 43, 1131–1138. 
Chu, J., and Sadler, K.C. (2009). New school in liver development: Lessons from zebrafish. 
Hepatology 50, 1656–1663. 
Cox, A.G., Saunders, D.C., Kelsey, P.B., Jr, Conway, A.A., Tesmenitsky, Y., Marchini, J.F., 
Brown, K.K., Stamler, J.S., Colagiovanni, D.B., Rosenthal, G.J., et al. (2013). S-Nitrosothiol 
Signaling Regulates Liver Development and Improves Outcome following Toxic Liver Injury. 
CellReports 1–14. 
Crosnier, C. (2005). Delta-Notch signalling controls commitment to a secretory fate in the 
zebrafish intestine. Development 132, 1093–1104. 
Day, C.P., and James, O.F. (1998). Steatohepatitis: a tale of two "hits"? Gastroenterology 114, 
842–845. 
Driever, W., Solnica-Krezel, L., Schier, A.F., Neuhauss, S.C., Malicki, J., Stemple, D.L., 
Stainier, D.Y., Zwartkruis, F., Abdelilah, S., Rangini, Z., et al. (1996). A genetic screen for 
mutations affecting embryogenesis in zebrafish. Development 123, 37–46. 
El-Serag, H.B. (2007). Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 37 Suppl 
2, S88–S94. 
Farber, J.W.J.A.R.B.M.P.S., Anderson, J.L., Bittman, R., Pack, M., and Farber, S.A. (2012). 
Visualization of Lipid Metabolism in the Zebrafish Intestine Reveals a Relationship between 
NPC1L1- Mediated Cholesterol Uptake and Dietary Fatty Acid. Chemistry & Biology 19, 913–
925. 
Farber, S.A., Pack, M., Ho, S.Y., Johnson, I.D., Wagner, D.S., Dosch, R., Mullins, M.C., 
Hendrickson, H.S., Hendrickson, E.K., and Halpern, M.E. (2001). Genetic analysis of digestive 
physiology using fluorescent phospholipid reporters. Science 292, 1385–1388. 
Felder, C.C., Briley, E.M., Axelrod, J., Simpson, J.T., Mackie, K., and Devane, W.A. (1993). 
Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid 
receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 90, 
7656–7660. 
Fukuda, K., and Kikuchi, Y. (2005). Endoderm development in vertebrates: fate mapping, 
induction and regional specification. Dev Growth Differ 47, 343–355. 
Garnaas, M.K., Cutting, C.C., Meyers, A., Kelsey, P.B., Harris, J.M., North, T.E., and Goessling, 
W. (2012). Rargb regulates organ laterality in a zebrafish model of right atrial isomerism. Dev 
Biol 372, 178–189. 
Goessling, W., Allen, R.S., Guan, X., Jin, P., Uchida, N., Dovey, M., Harris, J.M., Metzger, 
M.E., Bonifacino, A.C., Stroncek, D., et al. (2011). Prostaglandin E2 Enhances Human Cord 
Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman 
Primate Transplant Models. Stem Cell 8, 445–458. 
  28 
Goessling, W., North, T.E., Loewer, S., Lord, A.M., Lee, S., Stoick-Cooper, C.L., Weidinger, G., 
Puder, M., Daley, G.Q., Moon, R.T., et al. (2009). Genetic interaction of PGE2 and Wnt 
signaling regulates developmental specification of stem cells and regeneration. Cell 136, 1136–
1147. 
Goessling, W., North, T.E., Lord, A.M., Ceol, C., Lee, S., Weidinger, G., Bourque, C., 
Strijbosch, R., Haramis, A.-P., Puder, M., et al. (2008). APC mutant zebrafish uncover a 
changing temporal requirement for wnt signaling in liver development. Dev Biol 320, 161–174. 
Guzmán, M. (2003). Cannabinoids: potential anticancer agents. Nat Rev Cancer 3, 745–755. 
Haffter, P., Granato, M., Brand, M., Mullins, M.C., Hammerschmidt, M., Kane, D.A., Odenthal, 
J., van Eeden, F.J., Jiang, Y.J., Heisenberg, C.P., et al. (1996). The identification of genes with 
unique and essential functions in the development of the zebrafish, Danio rerio. Development 
123, 1–36. 
Haramis, A.-P.G., Hurlstone, A., van der Velden, Y., Begthel, H., van den Born, M., Offerhaus, 
G.J.A., and Clevers, H.C. (2006). Adenomatous polyposis coli-deficient zebrafish are susceptible 
to digestive tract neoplasia. EMBO Rep 7, 444–449. 
Hebbard, L., and George, J. (2011). Animal models of nonalcoholic fatty liver disease. Nat Rev 
Gastroenterol Hepatol 8, 35–44. 
Her, G.M., Chiang, C.-C., Chen, W.-Y., and Wu, J.-L. (2003). In vivo studies of liver-type fatty 
acid binding protein (L-FABP) gene expression in liver of transgenic zebrafish (Danio rerio). 
FEBS Lett 538, 125–133. 
Hézode, C., Roudot-Thoraval, F., Nguyen, S., Grenard, P., Julien, B., Zafrani, E.-S., Pawlotsky, 
J.-M., Pawlostky, J.-M., Dhumeaux, D., Lotersztajn, S., et al. (2005). Daily cannabis smoking as 
a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42, 63–71. 
Howe, K., Clark, M.D., Torroja, C.F., Torrance, J., Berthelot, C., Muffato, M., Collins, J.E., 
Humphray, S., McLaren, K., Matthews, L., et al. (2013). The zebrafish reference genome 
sequence and its relationship to the human genome. Nature 1–6. 
Izzo, A.A., and Sharkey, K.A. (2010). Cannabinoids and the gut: new developments and 
emerging concepts. Pharmacol Ther 126, 21–38. 
Jeong, W.-I., Osei-Hyiaman, D., Park, O., Liu, J., Bátkai, S., Mukhopadhyay, P., Horiguchi, N., 
Harvey-White, J., Marsicano, G., Lutz, B., et al. (2008). Paracrine activation of hepatic CB1 
receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7, 
227–235. 
Julien, B., Grenard, P., Teixeira-Clerc, F., Tran Van Nhieu, J., Li, L., Karsak, M., Zimmer, A., 
Mallat, A., and Lotersztajn, S. (2005). Antifibrogenic role of the cannabinoid receptor CB2 in the 
liver. Gastroenterology 128, 742–755. 
Kaser, S., Ebenbichler, C.F., and Tilg, H. (2010). Pharmacological and non-pharmacological 
  29 
treatment of non-alcoholic fatty liver disease. Int J Clin Pract 64, 968–983. 
Koteish, A., and Mae Diehl, A. (2002). Animal models of steatohepatitis. Best Pract Res Clin 
Gastroenterol 16, 679–690. 
Lieschke, G.J., and Currie, P.D. (2007). Animal models of human disease: zebrafish swim into 
view. Nat Rev Genet 8, 353–367. 
Loomba, R., and Sanyal, A.J. (2013). The global NAFLD epidemic. Nat Rev Gastroenterol 
Hepatol 10, 686–690. 
Lorent, K. (2004). Inhibition of Jagged-mediated Notch signaling disrupts zebrafish biliary 
development and generates multi-organ defects compatible with an Alagille syndrome 
phenocopy. Development 131, 5753–5766. 
Mallat, A., and Lotersztajn, S. (2008). Endocannabinoids and liver disease. I. Endocannabinoids 
and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol 294, G9–G12. 
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., and Bonner, T.I. (1990). Structure of 
a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564. 
McAllister, S.D., and Glass, M. (2002). CB(1) and CB(2) receptor-mediated signalling: a focus 
on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66, 161–171. 
Mehal, W.Z. (2013). The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev 
Gastroenterol Hepatol 10, 637–644. 
Migliarini, B., and Carnevali, O. (2008). Anandamide modulates growth and lipid metabolism in 
the zebrafish Danio rerio. Mol Cell Endocrinol 286, S12–S16. 
Migliarini, B., and Carnevali, O. (2009). A novel role for the endocannabinoid system during 
zebrafish development. Mol Cell Endocrinol 299, 172–177. 
Munro, S., Thomas, K.L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral 
receptor for cannabinoids. Nature 365, 61–65. 
Muñoz-Luque, J., Ros, J., Fernández-Varo, G., Tugues, S., Morales-Ruiz, M., Alvarez, C.E., 
Friedman, S.L., Arroyo, V., and Jiménez, W. (2008). Regression of fibrosis after chronic 
stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 324, 475–483. 
Nissim, S., Sherwood, R.I., Wucherpfennig, J., Saunders, D., Harris, J.M., Esain, V., Carroll, 
K.J., Frechette, G.M., Kim, A.J., Hwang, K.L., et al. (2014). Prostaglandin E2 regulates liver 
versus pancreas cell-fate decisions and endodermal outgrowth. Developmental Cell 28, 423–437. 
North, T.E., Babu, I.R., Vedder, L.M., Lord, A.M., Wishnok, J.S., Tannenbaum, S.R., Zon, L.I., 
and Goessling, W. (2010). PGE2-regulated wnt signaling and N-acetylcysteine are 
synergistically hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci USA 107, 
17315–17320. 
  30 
North, T.E., Goessling, W., Walkley, C.R., Lengerke, C., Kopani, K.R., Lord, A.M., Weber, G.J., 
Bowman, T.V., Jang, I.-H., Grosser, T., et al. (2007). Prostaglandin E2 regulates vertebrate 
haematopoietic stem cell homeostasis. Nature 447, 1007–1011. 
Osei-Hyiaman, D., DePetrillo, M., Harvey-White, J., Bannon, A.W., Cravatt, B.F., Kuhar, M.J., 
Mackie, K., Palkovits, M., and Kunos, G. (2005a). Cocaine- and amphetamine-related transcript 
is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81, 273–
282. 
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J., 
Mackie, K., Offertáler, L., Wang, L., et al. (2005b). Endocannabinoid activation at hepatic CB1 
receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115, 
1298–1305. 
Osei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W.-I., Bátkai, S., 
Marsicano, G., Lutz, B., Buettner, C., et al. (2008). Hepatic CB1 receptor is required for 
development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J 
Clin Invest 118, 3160–3169. 
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., and Pasquali, R. (2006). The emerging role of the 
endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27, 73–100. 
Passeri, M.J., Cinaroglu, A., Gao, C., and Sadler, K.C. (2009). Hepatic steatosis in response to 
acute alcohol exposure in zebrafish requires sterol regulatory element binding protein activation. 
Hepatology 49, 443–452. 
Patton, E.E., and Zon, L.I. (2001). The art and design of genetic screens: zebrafish. Nat Rev 
Genet 2, 956–966. 
Patton, E.E., Widlund, H.R., Kutok, J.L., Kopani, K.R., Amatruda, J.F., Murphey, R.D., 
Berghmans, S., Mayhall, E.A., Traver, D., Fletcher, C.D.M., et al. (2005). BRAF Mutations Are 
Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma. 
Current Biology 15, 249–254. 
Pisanti, S., Picardi, P., D’Alessandro, A., Laezza, C., and Bifulco, M. (2013). The 
endocannabinoid signaling system in cancer. Trends Pharmacol Sci 34, 273–282. 
Rekha, R.D., Amali, A.A., Her, G.M., Yeh, Y.H., Gong, H.-Y., Hu, S.-Y., Lin, G.-H., and Wu, 
J.-L. (2008). Thioacetamide accelerates steatohepatitis, cirrhosis and HCC by expressing HCV 
core protein in transgenic zebrafish Danio rerio. Toxicology 243, 11–22. 
Rodriguez-Martin, I., Herrero-Turrion, M.J., Marron Fdez de Velasco, E., Gonzalez-Sarmiento, 
R., and Rodriguez, R.E. (2007). Characterization of two duplicate zebrafish Cb2-like 
cannabinoid receptors. Gene 389, 36–44. 
Sadler, K.C., Amsterdam, A., Soroka, C., Boyer, J., and Hopkins, N. (2005). A genetic screen in 
zebrafish identifies the mutants vps18, nf2 and foie gras as models of liver disease. Development 
132, 3561–3572. 
  31 
Sadler, K.C., Krahn, K.N., Gaur, N.A., and Ukomadu, C. (2007). Liver growth in the embryo 
and during liver regeneration in zebrafish requires the cell cycle regulator, uhrf1. Proc Natl Acad 
Sci USA 104, 1570–1575. 
Sakaguchi, T.F., Sadler, K.C., Crosnier, C., and Stainier, D.Y.R. (2008). Endothelial Signals 
Modulate Hepatocyte Apicobasal Polarization in Zebrafish. Current Biology 18, 1565–1571. 
Shin, D., Shin, C.H., Tucker, J., Ober, E.A., Rentzsch, F., Poss, K.D., Hammerschmidt, M., 
Mullins, M.C., and Stainier, D.Y.R. (2007). Bmp and Fgf signaling are essential for liver 
specification in zebrafish. Development 134, 2041–2050. 
Si-Tayeb, K., Lemaigre, F.P., and Duncan, S.A. (2010). Organogenesis and Development of the 
Liver. Developmental Cell 18, 175–189. 
Siegmund, S.V., and Schwabe, R.F. (2008). Endocannabinoids and liver disease. II. 
Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest 
Liver Physiol 294, G357–G362. 
Silvestri, C., and Di Marzo, V. (2013). The Endocannabinoid System in Energy Homeostasis and 
the Etiopathology of Metabolic Disorders. Cell Metab 17, 475–490. 
Stainier, D.Y.R. (2002). A glimpse into the molecular entrails of endoderm formation. Genes 
Dev 16, 893–907. 
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., and 
Waku, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in 
brain. Biochem Biophys Res Commun 215, 89–97. 
Tainaka, T., Shimada, Y., Kuroyanagi, J., Zang, L., Oka, T., Nishimura, Y., Nishimura, N., and 
Tanaka, T. (2011). Transcriptome analysis of anti-fatty liver action byCampari tomato using a 
zebrafish diet-inducedobesity model. Nutr Metab (Lond) 8, 88. 
Tam, J., Vemuri, V.K., Liu, J., Bátkai, S., Mukhopadhyay, B., Godlewski, G., Osei-Hyiaman, D., 
Ohnuma, S., Ambudkar, S.V., Pickel, J., et al. (2010). Peripheral CB1 cannabinoid receptor 
blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120, 2953–
2966. 
Teixeira-Clerc, F., Belot, M.-P., Manin, S., Deveaux, V., Cadoudal, T., Chobert, M.-N., Louvet, 
A., Zimmer, A., Tordjmann, T., Mallat, A., et al. (2010). Beneficial paracrine effects of 
cannabinoid receptor 2 on liver injury and regeneration. Hepatology 52, 1049–1059. 
Tobin, D.M., Vary, J.C., Jr, Ray, J.P., Walsh, G.S., Dunstan, S.J., Bang, N.D., Hagge, D.A., 
Khadge, S., King, M.-C., Hawn, T.R., et al. (2010). The lta4h Locus Modulates Susceptibility to 
Mycobacterial Infection in Zebrafish and Humans. Cell 140, 717–730. 
van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J.S., Ho, V., 
Hebbard, L.W., Douglas, M.W., et al. (2010). Hepatitis C virus induces the cannabinoid receptor 
1. PLoS ONE 5. 
  32 
VanSaun, M.N., Lee, I.K., Washington, M.K., Matrisian, L., and Gorden, D.L. (2009). High fat 
diet induced hepatic steatosis establishes a permissive microenvironment for colorectal 
metastases and promotes primary dysplasia in a murine model. Am J Pathol 175, 355–364. 
White, R.M., Cech, J., Ratanasirintrawoot, S., Lin, C.Y., Rahl, P.B., Burke, C.J., Langdon, E., 
Tomlinson, M.L., Mosher, J., Kaufman, C., et al. (2011). DHODH modulates transcriptional 
elongation in the neural crest and melanoma. Nature 471, 518–522. 
Wilkins, B.J., Gong, W., and Pack, M. (2014). Gene Expression Patterns. Gene Expression 
Patterns 14, 62–68. 
Wittamer, V., Bertrand, J.Y., Gutschow, P.W., and Traver, D. (2011). Characterization of the 
mononuclear phagocyte system in zebrafish. Blood 117, 7126–7135. 
Wree, A., Broderick, L., Canbay, A., Hoffman, H.M., and Feldstein, A.E. (2013). From NAFLD 
to NASH to cirrhosis—new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 10, 
627–636. 
Yin, H., Evason, K.J., Maher, J.J., and Stainier, Y.R. (2012). The bHLH transcription factor 
Hand2 marks hepatic stellate cells in zebrafish: Analysis of stellate cell entry into the developing 
liver. Hepatology 56, 1958–1970. 
Zorn, A.M. (2008). Liver development. Stembook 1–26. 
 
  
  33 
Chapter 2: Cannabinoid receptors regulate hepatic differentiation and 
metabolism during development 
 
  34 
Cannabinoid receptors regulate hepatic differentiation and metabolism during 
development 
Leah Y. Liu1, Bani Mukhopadhyay2, Resat Cinar2, George Kunos2, Trista E. North3,4, Wolfram 
Goessling1,4,5,6,7 
 
1 Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 
02115, USA 
2 Laboratory of Physiological Studies, National Institute on Alcohol Abuse and Alcoholism, 
Bethesda, MD 20982, USA 
3Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 
Boston, MA 02115, USA 
4Harvard Stem Cell Institute, Cambridge, MA 02138, USA 
5 Gastroenterology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, 
MA 02115, USA 
6Dana-Farber Cancer Institute, Boston, MA 02215, USA 
7Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA 
 
This chapter contains a manuscript in revision at Development. It has been modified to fit the 
style of this dissertation. Supplemental data, additional, and ongoing experiments can be found in 
the Appendices. 
 
Author Contributions: L.Y.L and W.G. conceived and designed the experiments and analyzed 
the data. L.Y.L performed the zebrafish experiments and wrote the manuscript. B.M., R.C., and 
G.K. performed endocannabinoid measurements and shared mouse RNA sequencing data. All 
authors reviewed and edited the manuscript.  
 
  
  35 
Abstract  
 
  Endocannabinoid (EC) signaling is best known to mediate psychotropic effects and 
regulate appetite. In contrast, its roles in organ development and embryonic energy consumption 
remain unknown. Here, we demonstrate that genetic or chemical inhibition of cannabinoid 
receptor activity disrupts liver development and metabolic function in zebrafish, impacting 
differentiated hepatocytes but not hepatic specification: loss of EC signaling leads to smaller 
livers with fewer hepatocytes and impaired lipid handling. In contrast, EC agonists enhance liver 
growth during development. While liver mass recovers in cannabinoid receptor mutants, 
metabolic abnormalities persist throughout larval stages and adulthood. Metabolomic analysis 
reveals reduced content of methionine and its metabolic intermediates in receptor mutants. 
Extracts from mutant livers demonstrate reduced protein methylation. Treatment with exogenous 
methionine rescues the liver developmental defect, indicating a causal relationship between 
methionine deficiency and impaired liver growth. Using a candidate approach, we demonstrate 
that Sterol Regulatory Element-Binding Proteins (SREBPs) mediate the effect of EC signaling 
on methionine and rescue the liver defect in receptor mutants. Our work discovers a novel 
function for EC signaling during liver differentiation, and metabolomic analysis establishes a 
functional relationship between EC, methionine metabolism and SREBP signaling throughout 
liver development. 
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Introduction 
 
The energy requirements of a developing embryo influence and depend on the 
development of essential metabolic organs. The factors that impact energy consumption and 
metabolism during embryogenesis are not well understood. Defects in metabolic processing or 
insufficient nutrient utilization can disrupt differentiation and growth of essential organs, and 
different stages of development from stem cell maintenance to tissue specification may each 
require implementation of specific metabolic programming (Shyh-Chang et al., 2013; Tennessen 
et al., 2014). Disruption of developmental metabolism may impact adult organ function, as 
metabolites may also directly regulate essential acetylation and methylation processes, impacting 
epigenetic control of development (Shyh-Chang et al., 2013; Sinclair and Watkins, 2014). 
Impairment of cellular proliferation pathways can disrupt organogenesis, which can inhibit 
normal physiological functions and lead to long-term consequences for adult metabolic 
homeostasis. Here, we show that endocannabinoid (EC) signaling is required for normal 
embryonic liver development and function. As a central metabolic organ, the liver is essential for 
synthesis of metabolic enzymes and homeostatic control of glucose and lipids. Disruptions in 
these processes contribute to the development of diabetes, obesity, and chronic liver disease. 
Elucidating the genetic pathways and mechanisms regulating developmental metabolism and 
subsequent pathogenic processes can lead to early interventions in individuals with genetic 
disease predisposition.  
The endocannabinoid (EC) signaling pathway has predominantly been explored for its 
effects in the central nervous system (CNS), such as regulating appetite, mood, and pain (Castillo 
et al., 2012). In contrast, its function during embryonic development is unknown. The effects of 
ECs are mainly mediated by two principal G protein-coupled receptors, CB1 and CB2. CB1 is 
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primarily expressed in the CNS where it promotes appetite control (Maccarrone et al., 2010; 
Matsuda et al., 1990), while CB2 acts in immune cells and the gastrointestinal tract (Munro et al., 
1993). Although cannabinoids have been shown to regulate appetite in the CNS and 
independently in peripheral tissues, how these receptors influence embryonic metabolism and 
liver function via downstream targets has not been studied.  
In this study, we discover that cannabinoid receptors CB1 and CB2 are required for 
normal hepatocyte differentiation during embryonic development in the zebrafish. Disrupted EC 
activity leads to diminished and immature hepatocytes, impaired lipase activity and biliary lipid 
excretion. EC signaling orchestrates critical metabolic functions during early nutritional 
transitions, and the aberrations in liver physiology in receptor mutants persist in larval and adult 
zebrafish. Polar metabolomics analysis reveals dysregulation of methionine and its metabolic 
intermediates as a consequence of disrupted EC signaling. This process is mediated by SREBP 
genes, and both supplementation with methionine and overexpression of SREBPs rescues the 
developmental liver defects in zebrafish larvae. Our work uncovers a previously unrecognized 
relationship between EC signaling, liver development, and the regulation of metabolic 
homeostasis during development. 
 
Results 
 
Inhibition of signaling through CB1 and CB2 receptors impacts liver development 
We conducted a chemical screen in zebrafish to identify novel regulators of liver 
development (Garnaas et al., 2012). Cannabinoid agonists increased liver size, as determined by 
transgenic hepatocyte reporter fatty acid binding protein 10a (fabp10a):GFP expression at 72 
hours post fertilization (hpf) (Figure 2-1, A). To confirm the screen results, we exposed zebrafish 
embryos to CB1 and CB2 agonists and antagonists from 18-72 hpf at a concentration of 1 µM, as 
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determined by a dosage curve, followed by analysis of liver size at 72 hpf using in situ 
hybridization (ISH) for fabp10a. Compared to DMSO-treated control, the nonselective CB1/CB2 
agonists O2545 (Martin et al., 2006), the CB1 agonist Leelamine hydrochloride (L-HCl), and the 
CB2 agonist JWH015 increased liver size, while the antagonists Rimonabant and AM630, 
targeting CB1 and CB2 respectively, diminished liver formation (Figure 2-1, B-C). These 
chemical studies suggest an important role for EC signaling in liver development. 
Expression of zebrafish receptor homologs cnr1 and cnr2 is conserved in the liver and 
CNS during development at 24, 48, and 72 hpf, indicating the ability of the liver primordium to 
respond to EC agonists (Figure S2-1, in appendix). To genetically confirm the role of 
cannabinoid receptors during liver development, we generated cnr1-/- and cnr2-/- knockout 
zebrafish by constructing transcription activator-like effector nucleases (TALENs) (Sander et al., 
2011) targeting the first exon of the cnr1 and cnr2 genes  (Figure S2-2, A-B, in appendix).  
To avoid possible off-target effects of TALENs, animals were outcrossed for at least 3 
generations. cnr1-/- and cnr2-/- animals survived to adulthood, were fertile, and exhibited no gross 
morphological defects during development. Compared to wild-type embryos, liver size in both 
homozygous receptor mutants was significantly decreased at 72 hpf, as assessed by fabp10a in 
situ hybridization, and consistent with the chemical studies (Figure 2-1, D). Heterozygous 
mutants did not exhibit any liver size differences compared to wild type sibling controls (Figure 
S2-2, C, in appendix). Changes in liver size and hepatic gene expression were confirmed and 
quantified by measuring liver morphometrics in micrographs after ISH (Figure 2-1, E) and 
quantitative PCR (qPCR) for fabp10a, revealing a 50% decrease (Figure 2-1, F). Quantification 
of GFP-positive hepatocytes by FACS analysis in drug-treated and morpholino-injected 
Tg(fabp10a:GFP) reporter embryos demonstrated an increased cell number with agonist 
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treatment, while hepatocytes were diminished after chemical or genetic inactivation of cnr1 or 
cnr2 (Figure S2-2, D-E, in appendix). These findings were further corroborated by quantification 
of cnr1 and cnr2 morphant liver sizes in the Tg(fabp10a:GFP) hepatocyte reporter line, 
revealing consistent phenotypes and smaller livers at 72 hpf (Figure S2-2, F, in appendix). These 
combined results from chemical modulation, morpholino knockdown, and engineered mutants 
establish that cnr1 and cnr2 are required for normal liver development in zebrafish.  
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Figure 2-1 (next page). Chemical and genetic modulation of endocannabinoid signaling alters 
liver size during development 
A) Cannabinoid receptor agonists from chemical screen that increased liver size.  
B) Liver size distribution across clutches of zebrafish embryos treated with 1 µM of CB agonists 
and antagonists from 18-72 hpf, as assessed by visual inspection. Treatment with agonists shifted 
the liver size distribution toward “large” livers while treatment with antagonists shifted the liver 
size distribution toward “small” livers.  
C) in situ hybridization for fabp10a in zebrafish embryos at 72 hpf after treatment with 1 µM of 
CB drugs from 18-72 hpf. Scale bar = 0.2 mm. 
D) Liver size distribution and representative in situ hybridization images showing decreased 
fabp10a expression in cnr1-/- and cnr2-/- mutants. Chi-squared analysis, n>50 embryos, 
***p<0.001 compared to cnr1-/- and **p<0.01 compared to cnr2-/-. Scale bar = 0.2 mm. 
E) Quantification of liver size in cnr1-/- and cnr2-/- mutants based on liver morphometric 
measurements using ImageJ. Data are represented as mean ± s.e.m with one-way ANOVA 
analysis, n > 30 samples, ****p<0.0001 for wild-type vs. cnr1-/-  and wild-type vs. cnr2-/- .  
F) qPCR of the fabp10a gene showing decreased fabp10a expression in cannabinoid receptor 
mutants.  
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Figure 2-1 (continued) 
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To determine if the effects of cnr1 and cnr2 loss were specific to the liver, we examined 
other endodermal organs and proximal mesodermal organs: Intestinal development was also 
disrupted in cnr1 and cnr2 mutants, based on fabp2 expression at 72 hpf; however, exocrine 
pancreas development, as assessed by trypsin expression, was not affected, nor were markers for 
kidney (pax2a) and heart (cmlc2) (data not shown). To further delineate the temporal importance 
of EC signaling during the different stages of endoderm formation and differentiation, embryos 
were exposed to cannabinoid agonists from 18-24 hpf (endoderm specification), 24-48 hpf 
(hepatoblast population), or 48-72 hpf (hepatocyte differentiation and proliferation) (Figure 2-2, 
A). Only exposure to cannabinoid agonists from 48-72 hpf impacted liver size (Figure 2-2, B-C), 
and expression of the pan-endodermal marker foxA3 and the hepatoblast marker hhex at 48 hpf 
was unchanged in cnr1-/- and cnr2-/- mutants or morphants (Figure 2-2, D-F), indicating that the 
formation and growth of differentiated hepatocytes are impacted by lack of cannabinoid 
receptors, but earlier stages of endoderm development are not affected. Together, these results 
reveal that EC signaling is required for hepatocyte differentiation, but not earlier stages of liver 
development. 
  
  43 
Figure 2-2 (next page). Hepatocyte development is disrupted in cannabinoid receptor mutants 
without impairment of hepatic progenitors  
A) Schematic of drug exposure timeline to target the endoderm, hepatoblasts, and hepatocyte cell 
populations in the developing zebrafish embryo.  
B) Relative frequency of liver size distribution of zebrafish embryos treated with CB agonists 
during different stages of liver development. Treatment with both the CB1/CB2 agonist O2545 
1µM and with the CB2 agonist JWH015 1µM from 48-72hpf increased liver size, while earlier 
treatment had no effect. Embryos were scored based on fabp10a expression. Chi-squared 
analysis, n>30 embryos, O2545: ***p<0.001 compared to 48-72 hpf treatment group. JWH015: 
*p<0.05 compared to 48-72 hpf treatment group.  
C) Treatment with JWH015 from 48-72 hpf increases fabp10a expression in zebrafish embryos 
at 72 hpf. Scale bar = 0.2 mm. 
D) Graph and representative in situ hybridization images showing the size distribution of hhex 
expression after morpholino knockdown of cnr1 and cnr2. Morphant embryos do not show 
differences in hhex liver progenitor expression. Chi-squared analysis, n>30, p=NS. Scale bar = 
0.2 mm. 
E) Graph and representative in situ hybridization image of the size distribution of hhex 
expression in cnr1-/- and cnr2-/- mutants showing no difference in the hepatic progenitor 
population. Chi-squared analysis, n>30, p=NS. Scale bar = 0.2 mm. 
F) Graph and representative in situ hybridization image of the size distribution of foxA3 
expression in cnr1-/- and cnr2-/- mutants showing no difference in the endoderm population. Size 
distribution comparisons were made using Chi-squared analysis, n>30, p=NS. Scale bar = 0.2 
mm.
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Figure 2-2 (continued)
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cnr1-/- and cnr2-/- mutants exhibit disrupted liver function  
In order to examine whether the impact on liver differentiation persisted beyond the 
initial stages of liver growth, liver size was examined in larval stages: liver size defects in cnr 
mutants are still observed at 96 hpf, but are diminished by 120 hpf (Figure S2-3, A-B, in 
appendix). To determine if the effect of cnr1 and cnr2 loss is restricted to liver size or cell 
number, we assessed liver cellular morphology in cnr1-/- and cnr2-/- mutants in histological 
sections at 120 hpf. cnr1-/- and cnr2-/- mutant hepatocytes show a more rounded and less mature 
appearance; also, the intestinal epithelium appears disorganized (Figure 2-3, A). PCNA 
expression was decreased in cnr1-/- and cnr2-/- mutants compared to wild type, indicating that 
reduced cell proliferation is responsible for the liver size differences (Figure S2-3, C, in 
appendix). Together, these data indicate that even though fabp10a expression in mutants at 120 
hpf has recovered, histological features remain abnormal into larval stages with cannabinoid 
receptor loss, consistent with the observed impact on liver differentiation. 
In order to determine whether EC signaling also affects other hepatic cell types, we 
investigated expression of the biliary epithelial marker 2F11 in 120 hpf larval sections. Wild-
type larvae exhibit compact and evenly distributed biliary epithelial cells; in contrast, cnr1-/- and 
cnr2-/- mutants showed impaired biliary tree formation with more clustered, less uniform 
appearance (Figure 2-3, B). To confirm these abnormalities in biliary morphology in vivo and to 
also visualize hepatic lipid metabolism, we administered BODIPY C5 fluorophore, which labels 
all organs where metabolites accumulate (Carten et al., 2011): At 144 hpf, wild type larval livers 
exhibit highly branched bile ducts; in contrast, both cnr1-/- and cnr2-/- mutant larvae are 
characterized by decreased branching. In addition, cnr2-/- mutants have accumulated lipid 
droplets in the liver, indicative of abnormal lipid handling (Figure 2-3, C). To further 
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characterize the role of EC signaling in lipid metabolism in the developing liver, we used the 
lipase reporter PED6: lipase-mediated cleavage of PED6 unquenches the fluorophore and results 
in a fluorescent signal in the intestine and gallbladder (Farber et al., 2001). Both cnr1-/- and cnr2-
/- mutants demonstrate reduced lipase activity at 120 hpf, as evidenced by little or no detectable 
gallbladder fluorescence (Figure 2-3, D). This indicates that the normal metabolic activities of 
the liver and intestines are disrupted in mutants. Disrupted lipid metabolism, potentially resulting 
from aberrant development of metabolic organs, indicates that CB1 and CB2 receptors are 
necessary not only for proper liver size, but also have important physiological functions for 
metabolic homeostasis. These results further demonstrate the value of zebrafish mutants to assess 
developmental aspects of liver metabolism and function during larval stages that are not feasible 
with morpholino studies. 
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Figure 2-3 (next page). Livers in cannabinoid receptor mutants eventually develop to normal 
size but continue to exhibit metabolic and functional defects  
A) H&E-stained transverse sections through 120 hpf larvae show that cnr1-/- and cnr2-/- mutants 
have altered hepatocyte morphology. Liver is outlined in white dashes and onset shows 
magnification of hepatocytes. Scale bar = 0.1 mm. 
B) Transverse sections of 120 hpf larvae stained with the biliary marker 2F11 and DAPI show an 
abnormal biliary tree in cnr1-/- and cnr2-/- mutants. Scale bar = 0.1 mm. 
C) Confocal microscopy images of livers in wild-type and cnr1-/- and cnr2-/- mutant larvae 
showing metabolism of the BODIPY C5 fluorophore throughout the liver’s biliary tree. cnr1-/- 
larvae have decreased biliary branching while the cnr2-/- mutants are characterized by lipid 
deposits throughout the liver.  
D) Examination of PED6 lipase reporter in cnr1-/- and cnr2-/- mutants shows decreased 
fluorescent activity. Larvae were scored as “normal” or “abnormal”, and representative images 
are shown. Scale bar = 0.2 mm. 
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Figure 2-3 (continued) 
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cnr1-/- and cnr2-/- mutants demonstrate differential susceptibility to metabolic injury  
In order to examine whether the observed changes in lipid handling during larval 
development also alter susceptibility to pathological levels of lipid accumulation, we used an 
established protocol (Passeri et al., 2009) to induce alcoholic steatosis. Zebrafish exposed to 2% 
ethanol from 96-120 hpf develop steatosis at an incidence of 50-60%, which can be visualized 
using whole mount Oil Red O staining (Figure S2-4, A-B, in appendix). cnr1-/-, but not cnr2-/- 
mutants are protected from steatosis, with hepatic Oil Red O staining only detectable in 19% of 
cnr1-/- larvae exposed to ethanol. hand2, a marker of zebrafish hepatic stellate cells, which are 
thought to mediate hepatic injury (Yin et al., 2012), is normally upregulated under liver injury 
conditions. Consistent with the Oil Red O findings, induction of hand2 was observed by in situ 
hybridization in cnr2-/-, but not cnr1-/- 120 hpf larvae exposed to ethanol (Figure S2-4, C-D, in 
appendix).  These findings were confirmed by corresponding observations from morpholino 
studies and by treatment with CB modulators (Figure S2-4, E-F, in appendix), and are consistent 
with reported studies on the differential role of CB receptors in steatosis development in mice 
(Jeong et al., 2008; Louvet et al., 2011a). To determine the impact of EC signaling on 
nutritionally induced hepatic steatosis, a much bigger clinical problem, we established an egg 
yolk feeding protocol to mimic a high-fat diet by exposing embryos to 3% egg yolk solution 
from 96-120 hpf. This treatment induces steatosis in 65% of exposed WT larvae, but in only 24% 
of cnr1-/- larvae (Figure S2-5, A-B, in appendix). Similar to ethanol feeding, co-treatment with 
CB1 antagonist or CB2 agonist also decreased hepatic steatosis incidence (Figure S2-5, C, in 
appendix. Our findings indicate that zebrafish mutants at larval stages have aberrant responses to 
metabolic insult, consistent with reported mammalian biology, further indicating that 
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developmental disruption of EC signaling affects lipid homeostasis and susceptibility to 
metabolic insult.  
 
cnr1-/- and cnr2-/- mutants have altered metabolism in adulthood 
In order to determine how much the observed developmental and metabolic defects 
impacted or persisted into adult organ homeostasis and metabolism, we examined adult livers at 
6 months. Levels of 2-arachidonoylglycerol (2-AG) (Sugiura et al., 1995) and anandamide 
(AEA) (Devane et al., 1992), the primary endogenous ligands for CB1 and CB2, in adult liver 
tissue from cnr1-/- and cnr2-/- mutant livers were not significantly different from wild-type 
controls, as determined by liquid chromatography/tandem mass spectrometry (Figure S2-6, A-B, 
in appendix). This is consistent with findings in the livers of CB1 knockout mice 
(Mukhopadhyay et al., 2011). Liver mass-to-body-mass ratios in 6-month old wild-type and 
cnr1-/- and cnr2-/- mutants were comparable (Figure S2-6, C-D, in appendix). However, liver 
histology was abnormal, with evidence of cholestasis and inflammatory infiltrates seen in cnr1-/- 
animals, and abnormal cellular morphology, suggesting fatty infiltration in cnr2-/- mutants on a 
regular diet, even in the absence of metabolic injury induction (Figure 2-4, A). Further, 
expression of the biliary epithelial marker 2F11 was severely diminished in both cnr1-/- and cnr2-
/- mutants (Figure 2-4, B). In order to reveal systemic consequences of altered lipid metabolism, 
blood was collected from adult zebrafish, which demonstrated significantly elevated triglycerides 
levels in cnr2-/- mutants compared to age-matched cnr1-/- mutants and wild-type controls (Figure 
2-4, C-D). These observations of abnormal architecture and metabolism in adult animals indicate 
that disruptions in liver formation or metabolic function at the earliest stages can negatively 
impact adult homeostasis and global lipid metabolism, even though normal liver size is 
ultimately achieved.   
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Figure 2-4 (next page). Metabolic dysregulation and aberrant histological features persist in 
adult cannabinoid receptor mutants  
A) H&E-stained adult liver sections show evidence of cholestasis (inset) and inflammatory 
infiltrates in cnr1-/- mutants, and abnormal cellular morphology, suggesting extensive steatosis in 
cnr2-/- mutants. Scale bar = 0.1 mm. 
B) Histological sections through adult zebrafish livers stained for the biliary marker 2F11 and 
DAPI reveal decreased and impaired biliary tree formation in cnr1-/- adult zebrafish and 
cholestatic deposition (arrows) in cnr2-/- mutants. Scale bar = 0.1 mm. 
C) Quantification of serum triglyceride content in blood collected from male (C) and female (D) 
cannabinoid receptor mutants.  Adult cnr2-/- zebrafish have double the triglyceride concentration 
compared to wild type and cnr1-/- fish. Data are represented as mean ± s.e.m, one-way ANOVA 
analysis, n > 5, **p<0.01 for wild-type compared to cnr2-/-. 
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Figure 2-4 (continued) 
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Defects in EC signaling affects methionine metabolism 
In order to better define the metabolites most affected by disrupted EC signaling and to 
uncover the metabolic pathways disrupted in cnr1-/- and cnr2-/- mutants that may be responsible 
for the observed phenotypes, we pursued metabolomic analysis using mass spectrometry (Yuan 
et al., 2012) on adult livers, detecting over 290 polar metabolites. Metabolites clustered 
according to genotype without substantial differences between males and females, revealing 
several significant changes in individual metabolites from cnr1-/- and cnr2-/- adult livers (Figure 
S2-7, A, in appendix). Methionine pathway intermediates were significantly altered between 
both mutants and wild-type conditions, including reduced levels of methionine, homocysteine, S-
adenosyl-homocysteine, cysteine, homoserine, serine, and S-adenosyl-methionine (Figure 2-5, 
A; Figure S2-7, B-C, in appendix), suggesting defects in methionine metabolism. In order to 
further determine whether methionine metabolism was substantially affected by disrupted EC 
signaling, expression of key metabolic enzymes was examined by qPCR. S-
adenosylhomocysteine hydrolase (ahcy) and spermidine synthase (srm) were downregulated in 
mutant larvae, while methylenetetrahydrofolate reductase (mthfr) was upregulated (Figure 2-5, 
B). To confirm genetic conservation of these findings in a mammalian model, we re-analyzed 
previously published RNA sequencing data from CB1 knockout mouse livers (Mukhopadhyay et 
al., 2011). The expression levels of most methionine metabolism pathway enzymes were 
correspondingly downregulated in CB1 knockout mice (Figure 2-5, C). These results reveal that 
loss of either cannabinoid receptor in mice and zebrafish leads to dysregulation of the methionine 
pathway. Because methionine generates methyl groups for a variety of physiological and 
molecular functions, we examined global protein methylation levels in 120 hpf larvae or adult 
livers in cnr1-/- and cnr2-/- mutants. Levels of methylated protein were diminished in mutant 
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protein lysate based on detection of methyl-lysine in 120 hpf cnr1-/- and cnr2-/- mutants, 
consistent with a global decrease in methionine concentration (Figure 2-5, D). These data 
indicate that polar metabolomics identified methionine metabolism to be severely impacted in 
cnr1-/- and cnr2-/- mutants, which affects global protein methylation status, thereby having 
potential impact on a multitude of other cellular functions. 
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Figure 2-5 (next page). Polar metabolomics analysis reveals decreased levels of methionine 
metabolism intermediates 
A) Intermediates of the methionine metabolism pathway are decreased in both cnr1-/- and cnr2-/- 
mutant adult female liver tissue. Metabolites in male zebrafish showed similar decreases (Figure 
S2-7, in appedix). Data are represented as mean ± s.e.m, n=3. 
B) Enzymes involved in methionine metabolism are dysregulated in cnr1-/- and cnr2-/- larvae. 
adenosylhomocysteinase (ahcy) and spermidine synthase (srm) are downregulated, while mthfr is 
upregulated. n=3, ***p<0.001 and *p<0.05 for expression levels of enzyme in mutant compared 
to its control.  
C) RNA sequencing analysis shows that expression of methionine metabolism enzymes in wild-
type compared to CB1 knockout mice is highly dysregulated.  
D) Western blot of methylated lysine in total protein from cnr1-/- and cnr2-/- larvae at 120 hpf 
shows decreased and altered pattern of methylation in both mutants. 
 
  56 
Figure 2-5 (continued) 
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Methionine rescues liver development defects in cannabinoid mutants 
In order to determine if the observed changes in methionine metabolism are directly 
responsible for the observed liver phenotypes in cnr mutants during development, cnr1-/- and 
cnr2-/- mutant embryos were exposed to methionine metabolism intermediates. Treatment with 
methionine or cysteine at physiological concentrations (100 µM) from 24-72 hpf rescued the 
liver size defect in cnr1-/- and cnr2-/- mutants at 72 hpf (Figure 2-6, A-B). In addition, treatment 
of methionine or cysteine protected cnr2-/- mutants but not cnr1-/- or wild type Tu fish from 
alcohol-induced steatosis (Figure 2- 6, C-D). These data demonstrate that methionine 
supplementation not only rescues the developmental defect of hepatocyte differentiation, but also 
modulates the observed metabolic injury phenotypes in cnr2-/- mutants. 
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Figure 2-6 (next page). Treatment with methionine and cysteine can rescue liver development 
defects in cannabinoid receptor mutants 
A) Box plot with liver morphometric measurements of cnr1-/- and cnr2-/- mutants before and after 
treatment with 100 µM methionine and cysteine from 24-72 hpf. Both amino acids rescued the 
liver size defect in cannabinoid receptor mutants. Data are represented as mean ± s.e.m, one-way 
ANOVA analysis, n > 20 samples, ***p<0.001 for cnr1-/- compared to methionine treatment, 
**p<0.01 for cnr2-/- compared to methionine treatment and *p<0.05 for cnr2-/- compared to 
cysteine treatment. 
B) Representative in situ hybridization images of fabp10a expression in 72 hpf embryos. Scale 
bar = 0.2 mm. 
C) Graph showing percentage of larvae with fatty liver after ethanol-induced liver injury and  
with methionine or cysteine treatment. Treatment with the amino acids prevented fatty liver in 
cnr2-/- mutants. Fisher’s Exact test, n >30 samples, *p<0.05 and **p<0.01 comparing cnr2-/- to 
methionine or cysteine treatment.  
D) cnr2-/- embryos were exposed to 2% ethanol alone or co-treated with methionine or cysteine 
from 96-120 hpf and scored for fatty liver based on ORO staining. Scale bar = 0.2 mm. 
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Figure 2-6 (continued) 
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SREBP mediates the effects of EC signaling 
In order to characterize a potential regulator of methionine metabolism that mediates the 
effect of EC, we employed a candidate approach: Prior studies in C. elegans have shown that 
expression of genes involved in one-carbon metabolism is dependent on sterol regulatory 
element-binding proteins (SREBP) (Walker et al., 2011). We examined expression of zebrafish 
homologs srebf1 and srebf2 in cnr1-/- and cnr2-/- mutants at 120 hpf and adult livers, and found 
them to be downregulated compared to wild-type control (Figure 2-7, A). Furthermore, analysis 
of available expression data in CB1 knockout mice (Mukhopadhyay et al., 2011) revealed similar 
downregulation of Srebf1 and Srebf2 (Figure 2-7, B). 
To determine if SREBPs are functionally relevant for hepatocyte differentiation, we 
performed morpholino-mediated knockdown of srebf1 and srebf2, which resulted in decreased 
liver formation at 72 hpf that could not be rescued by exposure to cannabinoid agonists (Figure 
2-7, C-D and Figure S2-7, D-E, in appendix), indicating that srebf genes function downstream of 
cannabinoid receptors. To determine a direct relationship between cannabinoid receptors and 
srebfs, we overexpressed srebf1 and srebf2 in early development by injecting mRNA in one-cell 
stage zebrafish embryos and analyzed liver size at 72 hpf. Both srebf1 and srebf2 overexpression 
rescued liver size in cnr1-/- and cnr2-/- mutants (Figure 2-7, E-F), demonstrating the importance 
of signaling through the cannabinoid receptors via SREBPs during liver development. EC 
signaling therefore functions in both development and metabolism through SREBP-dependent 
control of one-carbon metabolism.  
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Figure 2-7 (next page). Endocannabinoid signaling regulates methionine metabolism via 
SREBPs in cannabinoid receptor mutants 
A) srebf1 and srebf2 levels are downregulated in cnr1-/- and cnr2-/- 120 hpf mutants, as measured 
by qPCR, but are more normalized in adult liver samples. n=3, ****p<0.0001, ***p<0.001, and 
**p<0.01 for expression levels of srebf1 or srebf2 in mutants vs. control. 
B) Relative expression of Srebf1 and Srebf2 is decreased in CB1 knockout mice compared to 
control.  
C) Box plot of liver morphometric measurements and D) representative in situ hybridization 
images at 72 hpf based showing reduced liver size of srebf1 morphants and failure of the CB1/2 
agonist O2545, CB1 agonist L-HCl, and CB2 agonist JWH015 treatment from 24-72 hpf to 
rescue liver growth when srebf1 is knocked down. Data are represented as mean  ± s.e.m with 
one-way ANOVA analysis, n > 20 samples, ***p<0.001 for Tu compared to srebf1 morpholino 
injection. Scale bar = 0.2 mm. 
E) Box plot and F) representative in situ hybridization images at 72 hpf based on liver 
morphometric measurements showing liver size of cnr1-/- and cnr2-/- mutants before and after 
overexpression of srebf1 and srebf2 mRNA. Both srebf1 and srebf2 were able to rescue the liver 
size defect in cannabinoid receptor mutants. Data are represented as mean ± s.e.m, one-way 
ANOVA analysis, n > 20, ***p<0.001 for cnr1-/- compared to srebf1 or srebf2 overexpression, 
**p<0.01 for cnr2-/- compared to srebf1 overexpression and ****p<0.0001 for cnr2-/- compared 
to srebf2 overexpression. Scale bar = 0.2 mm.
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Figure 2-7 (continued)
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Discussion 
 
  In this study, we discover the requirement of CB1 or CB2 cannabinoid receptor activity 
for normal liver development: loss of CB1 or CB2 signaling impairs hepatocyte differentiation, 
but not earlier stages of endoderm specification. EC signaling is also important for proper 
hepatic physiology and metabolism during development, with defects sustained into adulthood in 
cannabinoid receptor mutants. Methionine metabolism, via action of SREBPs, acts downstream 
of the cannabinoid receptors and is functionally responsible for the observed phenotypes, as 
methionine supplementation or SREBP overexpression reversed liver developmental and 
metabolic defects in mutants. This important signaling interaction demonstrates that despite 
recovery of liver size, functional consequences in differentiated adult tissue still occur in 
cannabinoid receptor mutants.  
 
Endocannabinoid signaling through cannabinoid receptors is required for liver development  
Our results demonstrate that early metabolic dysfunction and lack of a normal hepatocyte 
population during hepatogenesis impedes proper liver physiology throughout development, as 
indicated by functional abnormalities in our larval injury models and assessment of liver 
physiology in larvae and adults. cnr1 and cnr2 have been previously found to be expressed in the 
zebrafish CNS, and the endocannabinoid anandamide can modulate cnr1 expression in zebrafish 
(Lam et al., 2006; Martin et al., 2006; Migliarini and Carnevali, 2008; Migliarini and Carnevali, 
2009; Rodriguez-Martin et al., 2007). Even though EC signaling has been implicated in 
promoting trophoblast cell lineage differentiation (Sun et al., 2010) and neural development 
(Palazuelos et al., 2011; Psychoyos et al., 2012), the role of this pathway during vertebrate 
endoderm and liver development has not been investigated in detail. One indication that the EC 
pathway may affect embryonic development was observed in CB1 knockout ob/ob double 
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mutant mice, which have growth retardation and exacerbated glucose intolerance (Li et al., 2013), 
thus providing additional evidence that aberrations in metabolic regulation and developmental 
processes are highly associated. Our data also explain why adult CB1 and CB2 knockout mice 
have delayed or aberrant hepatocyte proliferation compared to wild type animals after partial 
hepatectomy (Mukhopadhyay et al., 2011; Teixeira-Clerc et al., 2010), as the recapitulation of 
proliferation-promoting developmental pathways has been shown to be important during liver 
regeneration (Goessling et al., 2008; Nissim et al., 2014; Yin et al., 2012). CB receptors have 
divergent roles in mediating hepatic fat accumulation in the adult: CB1 mediates hepatic 
steatosis (Jeong et al., 2008; Osei-Hyiaman et al., 2008; Ravinet Trillou et al., 2004), while CB2, 
acting on different cell populations in the liver, inhibits lipogenesis and inflammation (Deveaux 
et al., 2009; Julien et al., 2005; Louvet et al., 2011b). A previous transgenic zebrafish with 
inducible cnr1 expression also suggested the importance of this pathway for steatosis (Pai et al., 
2013). Our data on susceptibility to ethanol and diet-induced liver injury are highly consistent 
with these reports. Despite the documented divergent roles of CB1 and CB2 during hepatic 
steatosis induction, due to differential expression on hepatocytes versus stellate cells, their 
common role in promoting hepatocyte proliferation during development explains the 
observations that these receptors are also important for proliferation of liver tissue in the 
regenerating liver. 
 
Endocannabinoid signaling regulates methionine metabolism via SREBPs 
SREBPs are established downstream targets of EC signaling (Jeong et al., 2008; Osei-
Hyiaman et al., 2005). Although defects in EC signaling or methionine metabolism components 
have been independently shown to be associated with hepatic steatosis, fibrosis, or liver cancer 
(Huang et al., 2011; Mato et al., 2008; Pisanti et al., 2013), here we highlight a previously 
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unknown interaction between EC signaling, SREBP, and one-carbon metabolism. Methionine 
metabolism generates S-adenosyl methionine, which is required for a variety of physiological 
functions, including acting as a methyl donor for nucleic acid, phospholipid, and protein 
methylation. Methionine metabolism enzymes are conserved in zebrafish with the exception of 
methionine synthase, and are primarily expressed in the liver. The zebrafish mutant of S-
adenosylhomocysteine hydrolase (ahcy), the key enzyme metabolizing S-adenosylhomocysteine 
into adenosine and homocysteine, is characterized by steatosis and liver degeneration (Matthews 
et al., 2009), while mouse knockouts for the MAT1A, PEMT, GNMT, CBS, and MTHFR enzymes 
develop steatohepatitis and hepatocellular carcinoma, potentially via decreased methylation or 
AMPK inhibition (Mato et al., 2008). Interestingly, a methionine-choline deficient diet has long 
been used as a protocol to induce features of fatty liver disease in mouse models (Best et al., 
1936). Mammalian models for studying methionine metabolism enzymes also reveal the 
importance of this pathway for early development.  Knockout of methionine synthase leads to 
post-implantation embryonic death, while knockout of MTHFR leads to smaller body size and 
growth retardation (Chen et al., 2001; Swanson et al., 2001). Furthermore, restriction of 
methionine in pregnant sheep resulted in offspring with increased adiposity and altered 
methylation status (Sinclair et al., 2007), and general undernutrition can cause aberrant DNA 
methylation in the developing embryo that perturbs adult metabolic status (Radford et al., 2014). 
Methionine metabolism therefore appears to be integral for proper liver function and its 
disruption can set the stage for lasting metabolic dysfunction. Our studies discover EC signaling 
as a new regulator of methionine and its essential and global functions. 
SREBPs are responsible for promoting fatty acid and cholesterol uptake and synthesis 
and can act downstream of EC signaling in the liver, with levels that can be regulated in 
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zebrafish and mice by administration of anandamide (Migliarini and Carnevali, 2008; Osei-
Hyiaman et al., 2005; Pai et al., 2013).  In mice, modulation of dietary methionine can alter 
SREBP protein expression (Aissa et al., 2014), while studies in C. elegans show that expression 
of methionine metabolism genes are dependent on SREBP1 expression, and knockdown of these 
enzymes involved in one-carbon metabolism increases lipid accumulation (Walker et al., 2011). 
Furthermore, it was proposed that a feedback loop due to decreased one-carbon metabolism can 
activate SREBPs. Interestingly, DNA methylation of the triglyceride synthesis gene glycerol-3-
phosphate acyltransferase (GPAT1) in neonatal mice decreased SREBP-1c recruitment, whereas 
the opposite occurred in adult mice (Ehara et al., 2012). In our studies, overexpression of srebp1 
and srebp2 mRNA in cnr1-/- and cnr2-/- zebrafish embryos leads to restoration of normal liver 
size, providing evidence for a novel conserved signaling axis from cannabinoid receptors to 
methionine metabolism via SREBPs.  
 
Modulation of EC signaling to impact energy metabolism as a therapeutic approach  
Our findings allow new insights into common metabolic diseases such as hepatic 
steatosis, obesity, and diabetes. These diseases are all believed to have complex genetic causes, 
and patients with genetic variants or deficiencies of CNR1, CNR2, fatty acid amide hydrolase 
(FAAH), the enzyme that breaks down endocannabinoids, and methionine metabolism enzymes 
such as AHCY, PEMT, GNMT, MTHFR, CBS, have a higher likelihood of developing abnormal 
metabolic features or liver disease (Baric et al., 2004; Coppola et al., 2014; Feng et al., 2010; 
Floreani et al., 2009; Mato et al., 2008; Sipe et al., 2005). Our work gives strong evidence for 
either the developmental defect itself or an underlying metabolic abnormality that impacts adult 
liver homeostasis. This offers an exciting therapeutic opportunity for early interventions that may 
minimize disease phenotypes later in life. Adult cnr1-/- and cnr2-/- mutants exhibit abnormalities 
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in liver and biliary morphology, and particularly cnr2-/- mutant adult fish also have elevated 
serum triglyceride levels. Further study is required to determine whether rescue of the liver size 
defect in early development alone can prevent metabolic disease in adulthood, or whether 
methionine maintenance treatment in adulthood is required to provide a similar rescue. Here, we 
show that pathways uncovered in a zebrafish screen for novel regulators of liver development 
can reveal insights into developmental metabolism and adult liver homeostasis. We define a 
novel role for endocannabinoid signaling in promoting liver development, and discover that this 
pathway is essential in regulating methionine metabolism intermediates for liver homeostasis and 
function. 
Materials and Methods 
 
Zebrafish husbandry 
Zebrafish were maintained according to standard Institutional Animal Care and Use 
Committee guidelines.  
 
Generation of cnr1-/- and cnr2-/- mutants 
 TALE repeat arrays (http://zifit.partners.org/ZiFiT/) were designed to target cnr1 and 
cnr2 genes using the REAL system (Sander et al., 2011) and were cloned into TALEN vectors 
expressing FokI cleavage domains. TALEN mRNA pairs were injected into one-cell stage Tu 
embryos. Somatic mutation rates from pooled embryos were assessed (Sander et al., 2011). 
Injected fish were raised to adulthood and outcrossed. Founders were identified by assessing 
clutches for heterozygous progeny. Heterozygotes were raised to adulthood, genotyped, 
outcrossed for at least 3 generations, and incrossed to obtain homozygous mutants.  
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In situ hybridization:  
In situ hybridization was conducted on embryos fixed in paraformaldehyde using 
standard protocols (http://zfin.org/ZFIN/SD/ThisseProtocol.html). Changes in fabp10a 
expression at 72 hpf were scored using ImageJ to quantify liver size in images. All other 
expression patterns were scored as “small,” “normal,” and “large” within a population 
distribution, consistent with the quantitative size distribution. The percentage altered of the total 
population was then calculated for each genotype/treatment group. Chi-squared test, Fisher’s 
exact test, and one-way ANOVA analysis were used to compare changes in the scored 
populations. 
 
qPCR 
 RNA was extracted from pooled embryos or adult livers using Trizol and cDNA was 
generated using Superscript reagents (Invitrogen). qPCR was performed using SYBR Green 
Supermix (BioRad) and relative expression levels were calculated using the ΔΔCt method. 
Primers are listed in Table S2-1, in appendix.  
 
Morpholino injection 
Morpholino oligonucleotides (GeneTools, LLC, Philomath, OR) were designed against 
cnr1 (5’ GTGCTATCAACAACATACCTTTGTG 3’), cnr2 (5’ 
GTTCCAGTTTGTTCTCCATTTTCCC 3’), srebf1 (5’ 
AAGTGTCGTCAAAAGACAGATTCAT 3’), and srebf2 (5’ 
GCGTCCATGTTTCTCCACCTTCTCT 3’). Injections were performed at the one cell stage at a 
concentration of 100 µM or higher. A mismatch standard morpholino was used for control. 
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Oil Red O staining 
 Whole mount Oil Red O was conducted as previously described (Passeri et al., 2009). 
Embryos were scored based on presence of red lipid droplets in the liver. 
 
Immunohistochemistry 
 Whole livers dissected from adult zebrafish or whole embryos were fixed, embedded in 
paraffin, sectioned and stained with H&E using standard protocols. H&E-stained sections were 
examined by Jason Hornick, a board certified pathologist. Immunohistochemistry was performed 
using antibodies to PCNA (Anaspec) and 2F11 (Abcam) and either FITC fluorescent secondary 
antibody or HRP-conjugated secondary antibody.  
 
Analysis of fluorescent reporters in live embryos 
  To assess lipase activity, embryos were exposed to 0.1µg/mL of PED6  (Farber et al., 
2001) at 120 hpf for 6 hours, washed away, and then imaged using fluorescence microscopy.  
BODIPY-C5 fluorophore (Invitrogen) was utilized to observe lipid metabolism and digestive 
organ morphology in vivo. Embryos at 6 dpf were incubated in 6.4 µM BODIPY-C5 in 5% egg 
yolk solution for 4 hours, followed by confocal microscopy.  
 
Serum lipid tests 
 Plasma was collected from adult zebrafish from a tail incision (Babaei et al., 2013). We 
analyzed plasma triglyceride and cholesterol concentrations using microplate-based enzyme 
activity kits (Pointe Scientific).  
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Polar metabolomics 
 Lipids were extracted from zebrafish liver samples using previously described protocols 
(Yuan et al., 2012). Quantitative polar metabolomics profiling was performed using AB/SCIEX 
5000 QTRAP LC/MS/MS instrumentation.  
 
Western blotting 
Protein was extracted from pooled larvae populations at 120 hpf, and proteins resolved 
using SDS-PAGE. Presence of proteins with methylated-lysine was examined using anti-
methylated lysine (Abcam) and secondary antibody conjugated with HRP (Jackson 
Immunoresearch).  
 
Chemical exposure 
Cannabinoid agonists and antagonists were utilized at concentrations of 1 µM: O-2545, 
Leelamine hydrochloride (L-HCl), JWH015, AM630, Rimonabant (Chemicals Cayman 
Chemicals, Tocris). Methionine and cysteine (Sigma) exposure occurred at 100 µM. 
 
mRNA injection  
 srebf1 and srebf2 were amplified from wild type zebrafish cDNA using the following 
primers: srebf1  (5’AAGAGCATCCGAGGACAATG 3’, 5’ GTGTTCAGGTGGATGTGACG 
3’) and srebf2 (5’ TGTGAGTGAACGAGGAGACG 3’ 5’ GTTATGATGCAGCGTTGGTG 3’). 
After PCR amplification, polyadenylated mRNA was transcribed using the mMessage 
mMachine transcription kit (Ambion), and injected into one cell stage zebrafish embryos at a 
concentration of 100 pg/nl.  
 
 
 
  71 
Fluorescence activated cell sorting! 
Tg(fabp10a:GFP) embryos were manually dissociated for 10 minutes in a solution of 
0.25% trypsin. Cells were strained through 35 µm nylon mesh filter and analyzed on a BD 
FACSAria II flow cytometer as previously described (Goessling et al., 2008).  
 
Endocannabinoid measurements  
The tissue levels of endocannabinoids were measured by stable isotope dilution liquid 
chromatography/tandem mass spectrometry (LC-MS/MS) as described previously 
(Mukhopadhyay et al., 2011).  
 
Acknowledgements 
 
This work was supported by the NIH NIAAA F31AA022548 (L.Y.L) and NIDDK 
R01DK090311(W.G.). W.G. is a Pew Scholar in the Biomedical Sciences. We would like to 
thank Chris Simpson for histological preparation, Jason Hornick for histopathological analysis, 
John Asara for metabolomics assessment, Ruma Banerjee for helpful discussions, and staff of the 
Beth Israel Deaconess Medical Center and Brigham and Women’s Hospital fish facilities. There 
are no conflicts of interest to report. 
 
 
 
  
  72 
References  
 
Aissa, A. F., Tryndyak, V., de Conti, A., Melnyk, S., Gomes, T. D. U. H., Bianchi, M. L. P., 
James, S. J., Beland, F. A., Antunes, L. M. G. and Pogribny, I. P. (2014). Effect of 
methionine-deficient and methionine-supplemented diets on the hepatic one-carbon and lipid 
metabolism in mice. Mol. Nutr. Food Res. 58, 1502–1512. 
Babaei, F., Ramalingam, R., Tavendale, A., Liang, Y., Yan, L. S. K., Ajuh, P., Cheng, S. H. 
and Lam, Y. W. (2013). Novel Blood Collection Method Allows Plasma Proteome Analysis 
from Single Zebrafish. J. Proteome Res. 12, 1580–1590. 
Baric, I., Fumic, K., Glenn, B., Cuk, M., Schulze, A., Finkelstein, J. D., James, S. J., 
Mejaski-Bosnjak, V., Pazanin, L., Pogribny, I. P., et al. (2004). S-adenosylhomocysteine 
hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proc Natl 
Acad Sci USA 101, 4234–4239. 
Best, C. H., Mawson, M. E., McHenry, E. W. and Ridout, J. H. (1936). The effect of diets 
low in choline. J. Physiol. (Lond.) 86, 315–322. 
Carten, J. D., Bradford, M. K. and Farber, S. A. (2011). Visualizing digestive organ 
morphology and function using differential fatty acid metabolism in live zebrafish. Dev Biol 
360, 276–285. 
Castillo, P. E., Younts, T. J., Chávez, A. E. and Hashimotodani, Y. (2012). Endocannabinoid 
Signaling and Synaptic Function. Neuron 76, 70–81. 
Chen, Z., Karaplis, A. C., Ackerman, S. L., Pogribny, I. P., Melnyk, S., Lussier-Cacan, S., 
Chen, M. F., Pai, A., John, S. W., Smith, R. S., et al. (2001). Mice deficient in 
methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased 
methylation capacity, with neuropathology and aortic lipid deposition. Human Molecular 
Genetics 10, 433–443. 
Coppola, N., Zampino, R., Bellini, G., Macera, M., Marrone, A., Pisaturo, M., Boemio, A., 
Nobili, B., Pasquale, G., Maione, S., et al. (2014). Association Between a Polymorphism in 
Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis 
C. Clin. Gastroenterol. Hepatol. 12, 334–340. 
Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, 
D., Mandelbaum, A., Etinger, A. and Mechoulam, R. (1992). Isolation and structure of a 
brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949. 
Deveaux, V., Cadoudal, T., Ichigotani, Y., Teixeira-Clerc, F., Louvet, A., Manin, S., Nhieu, 
J. T.-V., Belot, M. P., Zimmer, A., Even, P., et al. (2009). Cannabinoid CB2 receptor 
potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS 
ONE 4, e5844. 
Ehara, T., Kamei, Y., Takahashi, M., Yuan, X., Kanai, S., Tamura, E., Tanaka, M., 
  73 
Yamazaki, T., Miura, S., Ezaki, O., et al. (2012). Role of DNA methylation in the 
regulation of lipogenic glycerol-3-phosphate acyltransferase 1 gene expression in the mouse 
neonatal liver. Diabetes 61, 2442–2450. 
Farber, S. A., Pack, M., Ho, S. Y., Johnson, I. D., Wagner, D. S., Dosch, R., Mullins, M. C., 
Hendrickson, H. S., Hendrickson, E. K. and Halpern, M. E. (2001). Genetic analysis of 
digestive physiology using fluorescent phospholipid reporters. Science 292, 1385–1388. 
Feng, Q., Jiang, L., Berg, R. L., Antonik, M., Mackinney, E., Gunnell-Santoro, J., Mccarty, 
C. A. and Wilke, R. A. (2010). A Common CNR1 (Cannabinoid Receptor 1) Haplotype 
Attenuates the Decrease in HDL Cholesterol That Typically Accompanies Weight Gain. 
PLoS ONE 5, e15779. 
Floreani, A., Lazzari, R., Macchi, V., Porzionato, A., Variola, A., Colavito, D., Leon, A., 
Guido, M., Baldo, V., Caro, R., et al. (2009). Hepatic expression of endocannabinoid 
receptors and their novel polymorphisms in primary biliary cirrhosis. J Gastroenterol 45, 
68–76. 
Garnaas, M. K., Cutting, C. C., Meyers, A., Kelsey, P. B., Harris, J. M., North, T. E. and 
Goessling, W. (2012). Rargb regulates organ laterality in a zebrafish model of right atrial 
isomerism. Dev Biol 372, 178–189. 
Goessling, W., North, T. E., Lord, A. M., Ceol, C., Lee, S., Weidinger, G., Bourque, C., 
Strijbosch, R., Haramis, A.-P., Puder, M., et al. (2008). APC mutant zebrafish uncover a 
changing temporal requirement for wnt signaling in liver development. Dev Biol 320, 161–
174. 
Huang, L., Quinn, M. A., Frampton, G. A., Golden, L. E. and Demorrow, S. (2011). Recent 
advances in the understanding of the role of the endocannabinoid system in liver diseases. 
Dig Liver Dis 43, 188–193. 
Jeong, W.-I., Osei-Hyiaman, D., Park, O., Liu, J., Bátkai, S., Mukhopadhyay, P., Horiguchi, 
N., Harvey-White, J., Marsicano, G., Lutz, B., et al. (2008). Paracrine activation of 
hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty 
liver. Cell Metab 7, 227–235. 
Julien, B., Grenard, P., Teixeira-Clerc, F., Tran Van Nhieu, J., Li, L., Karsak, M., Zimmer, 
A., Mallat, A. and Lotersztajn, S. (2005). Antifibrogenic role of the cannabinoid receptor 
CB2 in the liver. Gastroenterology 128, 742–755. 
Lam, S. H., Wu, Y. L., Vega, V. B., Miller, L. D., Spitsbergen, J., Tong, Y., Zhan, H., 
Govindarajan, K. R., Lee, S., Mathavan, S., et al. (2006). Conservation of gene 
expression signatures between zebrafish and human liver tumors and tumor progression. Nat 
Biotechnol 24, 73–75. 
Li, Z., Schmidt, S. F. and Friedman, J. M. (2013). Developmental role for endocannabinoid 
signaling in regulating glucose metabolism and growth. Diabetes 62, 2359–2367. 
  74 
Louvet, A., Teixeira-Clerc, F., Chobert, M.-N., Deveaux, V., Pavoine, C., Zimmer, A., 
Pecker, F., Mallat, A. and Lotersztajn, S. (2011b). Cannabinoid CB2 receptors protect 
against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 54, 
1217–1226. 
Maccarrone, M., Gasperi, V., Catani, M. V., Diep, T. A., Dainese, E., Hansen, H. S. and 
Avigliano, L. (2010). The Endocannabinoid System and Its Relevance for Nutrition. Annu. 
Rev. Nutr. 30, 423–440. 
Martin, B. R., Wiley, J. L., Beletskaya, I., Sim-Selley, L. J., Smith, F. L., Dewey, W. L., 
Cottney, J., Adams, J., Baker, J., Hill, D., et al. (2006). Pharmacological characterization 
of novel water-soluble cannabinoids. J Pharmacol Exp Ther 318, 1230–1239. 
Mato, J. M., Martínez-Chantar, M. L. and Lu, S. C. (2008). Methionine Metabolism and 
Liver Disease. Annu. Rev. Nutr. 28, 273–293. 
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. and Bonner, T. I. (1990). 
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 
346, 561–564. 
Matthews, R. P., Lorent, K., Mañoral-Mobias, R., Huang, Y., Gong, W., Murray, I. V. J., 
Blair, I. A. and Pack, M. (2009). TNFalpha-dependent hepatic steatosis and liver 
degeneration caused by mutation of zebrafish S-adenosylhomocysteine hydrolase. 
Development 136, 865–875. 
Migliarini, B. and Carnevali, O. (2008). Anandamide modulates growth and lipid metabolism 
in the zebrafish Danio rerio. Mol Cell Endocrinol 286, S12–6. 
Migliarini, B. and Carnevali, O. (2009). A novel role for the endocannabinoid system during 
zebrafish development. Mol Cell Endocrinol 299, 172–177. 
Mukhopadhyay, B., Cinar, R., Yin, S., Liu, J., Tam, J., Godlewski, G., Harvey-White, J., 
Mordi, I., Cravatt, B. F., Lotersztajn, S., et al. (2011). Hyperactivation of anandamide 
synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in 
the regenerating liver. Proceedings of the National Academy of Sciences 108, 6323–6328. 
Munro, S., Thomas, K. L. and Abu-Shaar, M. (1993). Molecular characterization of a 
peripheral receptor for cannabinoids. Nature 365, 61–65. 
Nissim, S., Sherwood, R. I., Wucherpfennig, J., Saunders, D., Harris, J. M., Esain, V., 
Carroll, K. J., Frechette, G. M., Kim, A. J., Hwang, K. L., et al. (2014). Prostaglandin E2 
regulates liver versus pancreas cell-fate decisions and endodermal outgrowth. Developmental 
Cell 28, 423–437. 
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-
White, J., Mackie, K., Offertáler, L., Wang, L., et al. (2005). Endocannabinoid activation 
at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced 
obesity. J Clin Invest 115, 1298–1305. 
  75 
Osei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W.-I., Bátkai, 
S., Marsicano, G., Lutz, B., Buettner, C., et al. (2008). Hepatic CB1 receptor is required 
for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in 
mice. J Clin Invest 118, 3160–3169. 
Pai, W.-Y., Hsu, C.-C., Lai, C.-Y., Chang, T.-Z., Tsai, Y.-L. and Her, G. M. (2013). 
Cannabinoid receptor 1 promotes hepatic lipid accumulation and lipotoxicity through the 
induction of SREBP-1c expression in zebrafish. Transgenic Res 22, 823–838. 
Palazuelos, J., Ortega, Z., Diaz-Alonso, J., Guzmán, M. and Galve-Roperh, I. (2011). CB2 
cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling. 
Journal of Biological Chemistry 287, 1198–1209. 
Passeri, M. J., Cinaroglu, A., Gao, C. and Sadler, K. C. (2009). Hepatic steatosis in response 
to acute alcohol exposure in zebrafish requires sterol regulatory element binding protein 
activation. Hepatology 49, 443–452. 
Pisanti, S., Picardi, P., D’Alessandro, A., Laezza, C. and Bifulco, M. (2013). The 
endocannabinoid signaling system in cancer. Trends Pharmacol Sci 34, 273–282. 
Psychoyos, D., Vinod, K. Y., Cao, J., Xie, S., Hyson, R. L., Wlodarczyk, B., He, W., Cooper, 
T. B., Hungund, B. L. and Finnell, R. H. (2012). Cannabinoid Receptor 1 Signaling in 
Embryo Neurodevelopment. Birth Defects Res B 95, 137–150. 
Radford, E. J., Ito, M., Shi, H., Corish, J. A., Yamazawa, K., Isganaitis, E., Seisenberger, S., 
Hore, T. A., Reik, W., Erkek, S., et al. (2014). In utero undernourishment perturbs the 
adult sperm methylome and intergenerational metabolism. Science 345, 1255903–1255903. 
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M. and Soubrié, P. (2004). CB1 
cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity 
and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28, 640–648. 
Rodriguez-Martin, I., Herrero-Turrion, M. J., Marron Fdez de Velasco, E., Gonzalez-
Sarmiento, R. and Rodriguez, R. E. (2007). Characterization of two duplicate zebrafish 
Cb2-like cannabinoid receptors. Gene 389, 36–44. 
Sander, J. D., Cade, L., Khayter, C., Reyon, D., Peterson, R. T., Joung, J. K. and Yeh, J.-R. 
J. (2011). Targeted gene disruption in somatic zebrafish cells using engineered TALENs. 
Nat Biotechnol 29, 697–698. 
Shyh-Chang, N., Daley, G. Q. and Cantley, L. C. (2013). Stem cell metabolism in tissue 
development and aging. Development 140, 2535–2547. 
Sinclair, K. D. and Watkins, A. J. (2014). Parental diet, pregnancy outcomes and offspring 
health: metabolic determinants in developing oocytes and embryos. Reprod. Fertil. Dev. 26, 
99. 
Sinclair, K. D., Allegrucci, C., Singh, R., Gardner, D. S., Sebastian, S., Bispham, J., 
  76 
Thurston, A., Huntley, J. F., Rees, W. D., Maloney, C. A., et al. (2007). DNA methylation, 
insulin resistance, and blood pressure in offspring determined by maternal periconceptional 
B vitamin and methionine status. Proceedings of the National Academy of Sciences 104, 
19351–19356. 
Sipe, J. C., Waalen, J., Gerber, A. and Beutler, E. (2005). Overweight and obesity associated 
with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes Relat 
Metab Disord 29, 755–759. 
Sun, X., Xie, H., Yang, J., Wang, H., Bradshaw, H. B. and Dey, S. K. (2010). 
Endocannabinoid signaling directs differentiation of trophoblast cell lineages and 
placentation. Proceedings of the National Academy of Sciences 107, 16887–16892. 
Swanson, D. A., Liu, M. L., Baker, P. J., Garrett, L., Stitzel, M., Wu, J., Harris, M., 
Banerjee, R., Shane, B. and Brody, L. C. (2001). Targeted Disruption of the Methionine 
Synthase Gene in Mice. Molecular and Cellular Biology 21, 1058–1065. 
Teixeira-Clerc, F., Belot, M.-P., Manin, S., Deveaux, V., Cadoudal, T., Chobert, M.-N., 
Louvet, A., Zimmer, A., Tordjmann, T., Mallat, A., et al. (2010). Beneficial paracrine 
effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology 52, 1049–
1059. 
Tennessen, J. M., Bertagnolli, N. M., Evans, J., Sieber, M. H., Cox, J. and Thummel, C. S. 
(2014). Coordinated metabolic transitions during Drosophila embryogenesis and the onset of 
aerobic glycolysis. G3 (Bethesda) 4, 839–850. 
Walker, A. K., Jacobs, R. L., Watts, J. L., Rottiers, V., Jiang, K., Finnegan, D. M., Shioda, 
T., Hansen, M., Yang, F., Niebergall, L. J., et al. (2011). A Conserved SREBP-
1/Phosphatidylcholine Feedback Circuit RegulatesLipogenesis in Metazoans. Cell 147, 840–
852. 
Yin, H., Evason, K. J., Maher, J. J. and Stainier, Y. R. (2012). The bHLH transcription factor 
Hand2 marks hepatic stellate cells in zebrafish: Analysis of stellate cell entry into the 
developing liver. Hepatology 56, 1958–1970. 
Yuan, M., Breitkopf, S. B., Yang, X. and Asara, J. M. (2012). A positive/negative ion–
switching, targeted massspectrometry–based metabolomics platform forbodily fluids, cells, 
and fresh and fixed tissue. Nature Protocols 7, 872–881. 
 
 
 
  77 
Chapter 3: Functional validation of GWAS gene candidates for abnormal 
liver function during zebrafish liver development 
 
  
  78 
Functional validation of GWAS gene candidates for abnormal liver function during 
zebrafish liver development 
 
Leah Y. Liu1, Caroline S. Fox2,3, Trista E. North4,5, Wolfram Goessling1,5,6 
 
 
1 Genetics Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 
2 National Heart, Lung, and Blood Institute's Framingham Heart Study and the Center for 
Population Studies, Framingham, MA 
3 Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, 
Boston, 
4Department of Pathology, Beth Israel Deaconess Hospital, Harvard Medical School 
5Harvard Stem Cell Institute, Cambridge, MA 
6 Gastroenterology Division, Brigham and Women’s Hospital; Gastrointestinal Cancer Center, 
Dana-Farber Cancer Institute, Boston, MA 
 
This chapter contains the manuscript published in Disease Models and Mechanisms. 2013 Sept; 
6(5):1271-8. PMID 23813869. It has been modified to fit the style of this dissertation. 
Supplemental data can be found in the Appendix. 
Author contributions: L.Y.L., W.G., and T.E.N. conceived and designed the experiments, and 
analyzed the data. L.Y.L performed the experiments and wrote the manuscript. C.S.F provided 
GWAS data prior to publication.  
 
  79 
Abstract  
 
 Genome-wide association studies (GWAS) have revealed numerous associations between 
many phenotypes and gene candidates. Frequently, however, further elucidation of gene function 
has not been achieved. A recent GWAS identified 69 candidate genes associated with liver 
enzyme concentrations, which are clinical liver disease markers. To investigate their role in liver 
homeostasis, we narrowed down this list to 12 genes based on zebrafish orthology, zebrafish 
liver expression, and disease correlation. To assess the function of gene candidates during liver 
development, we assayed hepatic progenitors at 48 hours post fertilization (hpf) and hepatocytes 
at 72 hpf using in situ hybridization following morpholino knockdown in zebrafish embryos. 
Knockdown of three genes (pnpla3, pklr, and mapk10) decreased expression of hepatic 
progenitor cells, while knockdown of eight genes (pnpla3, cpn1, trib1, fads2, slc2a2, pklr, 
mapk10, and samm50) decreased cell-specific hepatocyte expression. We then induced liver 
injury in zebrafish embryos using acetaminophen exposure and observed changes in liver 
toxicity incidence in morphants. Prioritization of GWAS candidates and morpholino knockdown 
expedites the study of novel genes impacting liver development and represents a feasible method 
for initial assessment of candidate genes to instruct further mechanistic analyses. Our analysis 
can be extended to GWAS for additional disease-associated phenotypes.  
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Introduction 
 
Levels of liver enzymes such as alanine aminotransferase (ALT), alkaline phosphatase, 
and γ-glutamyl transferase are clinical markers of liver injury, and are used to diagnose and 
monitor alcoholic liver disease, non-alcoholic fatty liver disease, cirrhosis, hepatitis, and drug-
induced liver injury (Goessling and Friedman, 2005). Plasma concentrations of these enzymes 
can also be affected by heritable factors (Bathum et al., 2001), and investigating the genes 
influencing liver enzyme concentrations can shed light on the molecular mechanisms of liver 
disease. Previous genome-wide association studies (GWAS) have been conducted to uncover 
genetic loci associated with concentrations of plasma liver enzymes (Chambers et al., 2011; 
Yuan et al., 2008). Six loci were initially identified in a GWAS of 7,715 individuals (Yuan et al., 
2008) and 36 additional loci were identified in a second GWAS using a larger population of 
61,089 individuals, which increased the likelihood that additional genes reached statistical 
significance (Chambers et al., 2011). These 42 loci correspond to 69 probable candidate genes, 
which represent many novel associations and provide a remarkable resource for further 
investigation and functional insight into the disease mechanisms and molecular mediators 
involved in maintaining liver homeostasis. However, as with other GWAS, the size of this gene 
list can hinder further investigation of individual candidate genes due to the difficulty of 
selecting the most important or biologically relevant genes at each locus, combined with the lack 
of rapid and cost-effective screening methods to prioritize genes for follow-up. 
 Zebrafish embryos exhibit many characteristics ideal for functional validation of GWAS 
data, specifically rapid development, high fecundity, and population-level variation similar to 
humans since zebrafish are not inbred. In this study, we utilize the zebrafish embryo for 
functional characterization of a subset of genes found to influence liver enzyme levels in human 
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adults. Liver enzyme elevation in human patients is a specific measure, but reflective of a 
patient’s susceptibility to injury and overall assessment of liver function. Previous studies 
revealed that pathways regulating liver homeostasis in the adult are also important for embryonic 
liver development, indicating the possibility of eliciting organ-relevant phenotypic changes 
during organogenesis (Goessling et al., 2008). Furthermore, aspects of fatty liver disease and 
drug-induced liver injury can be modeled in both the zebrafish adult and embryo (North et al., 
2010; Passeri et al., 2009). We can also use hhex and fabp10a, genes specifying hepatic 
progenitors and hepatocytes, respectively, as markers of liver growth and maintenance, which 
are reflective of liver health and homeostasis and can be easily assessed in the zebrafish embryo. 
We therefore aimed to functionally validate 14 zebrafish gene isoforms representing 12 human 
candidate genes identified from a large GWAS, which were selected based on zebrafish 
conservation, expression profile, and disease correlation. We utilized morpholino knockdown of 
each candidate gene in the zebrafish embryo to screen for genes that impact liver development or 
liver injury. We found that a majority of the gene candidates were required for proper hepatocyte 
differentiation and a subset was also important for early specification of liver progenitors. 
Additionally, we discovered that susceptibility to acetaminophen-induced liver damage was 
altered after knockdown of three gene candidates. These results demonstrate the feasibility of 
using the zebrafish to characterize the function of genes identified in GWAS for liver physiology, 
and may be applicable to a wider variety of clinically obtained parameters. 
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Results 
 
Selection of candidate genes for knockdown 
  
 Chambers et al. identified 42 genetic loci corresponding to 69 candidate genes associated 
with concentrations of plasma liver enzymes. Many of these genes have been previously 
characterized to function in lipid and carbohydrate metabolism or biliary transport, but few have 
been implicated in liver disease specifically (Chambers et al., 2011). To simplify this list for 
further study in an in vivo model system, we developed a strategy based on genomic resources, 
expression analysis and available functional data: we first identified the 43 genes with zebrafish 
orthologs, some of which have a and b isoforms (Figure 3-1). We then utilized published 
resources in ZFIN (www.zfin.org) to assess known zebrafish expression information to 
determine liver-specific expression. Subsequently, we analyzed the metabolomic, gene ontology, 
and KEGG pathway data from the original GWAS (Chambers et al., 2011) in combination with 
literature searches to select 12 genes with liver or metabolic disease correlation, but without any 
previously known role in liver development. We included the five genes with zebrafish orthologs 
that had been previously associated with elevated ALT levels, and excluded the 26 genes without 
zebrafish orthologs and the 31 genes without known zebrafish expression in differentiated 
endodermal organs such as the liver or intestine. This final list includes six genes associated with 
ALT elevation and/or hepatic steatosis (MAPK10, CPN1, TRIB1, PNPLA3, SAMM50, MICAL3) 
(Chambers et al., 2011; Sookoian and Pirola, 2011; Yuan et al., 2008). In addition, five genes are 
expressed in the zebrafish liver and are associated with abnormal metabolism: SLC2A2, encoding 
the glucose transporter glut2, and PKLR are associated with type II diabetes mellitus (Chambers 
et al., 2011; Hasstedt et al., 2008; Laukkanen et al., 2005); FADS2 is associated with an altered 
metabolome (Chambers et al., 2011; Rzehak et al., 2010; Schaeffer, 2006); ALDOB is expressed 
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in the developing zebrafish liver and gut and implicated in carbohydrate metabolism (Chambers 
et al., 2011; Coffee and Tolan, 2010; Esposito et al., 2010). MIF is involved in lipid metabolism, 
immune function and fibrosis (Chambers et al., 2011; Heinrichs et al., 2011; Verschuren et al., 
2009). Finally, EFNA1 is globally expressed in the early zebrafish embryo implicated in multiple 
developmental signaling pathways and cancer (Chambers et al., 2011; Cui et al., 2009) (Table 3-
1).  
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Figure 3-1 (next page). Schematic of conditions used to choose GWAS candidates for 
functional validation. We utilized the ZFIN database and metabolomic, disease correlation, and 
molecular pathway data from the liver enzyme GWAS to select 14 zebrafish genes for 
morpholino knockdown. We then analyzed response to acute liver injury, hepatic progenitors, 
and hepatocytes in morphant and control embryos to elucidate the function of candidate genes 
during development. 
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Figure 3-1 (continued) 
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Table 3-1: 12 candidate genes for knockdown in zebrafish embryos 
Gene Full Name 
PNPLA3 patatin-like phospholipase domain-containing protein 3 
CPN1 carboxypeptidase N catalytic chain 
 
TRIB1 tribbles homolog 1 
 
FADS2 fatty acid desaturase 2 
MIF macrophage migration inhibitory factor 
SLC2A2 solute carrier family 2 member 2 
PKLR pyruvate kinase isozymes liver and RBC 
MAPK10 MAP kinase 10 
ALDOB aldolase B, fructose-bisphosphate 
EFNA1 ephrin A1  
SAMM50 sorting and assembly machinery component 50 homolog 
MICAL3 microtubule-associated monoxygenase 
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Knockdown of gene candidates impacts hepatic progenitor populations 
 
 We designed morpholino antisense oligonucleotides to target both the ATG site (Table 3-
2, in appendix) and splice sites (Table 3-3, in appendix) of 14 zebrafish candidate genes, 
corresponding to 12 human genes found to influence plasma liver enzyme levels (EFNA1 and 
MICAL3 both have two zebrafish isoforms). We sequenced the target region of the ATG-site 
morpholino for each gene in both AB and Tubingen zebrafish strains to verify absence of 
polymorphic variation in these regions that could influence morpholino activity (Table S3-1, in 
appendix). Plasma liver enzyme levels are commonly used as clinical indicators of liver damage 
and most of the candidate genes listed in Table 3-1 are implicated in hepatic steatosis and lipid or 
carbohydrate metabolism. Genes governing adult liver homeostasis may also be important for 
liver specification and differentiation during embryonic development. In order to assess the 
impact of the candidate genes on hepatic development, we analyzed the expression of the hepatic 
progenitor marker hhex by in situ hybridization at 48 hours post fertilization (hpf) after 
morpholino injection and compared to siblings injected with a standard morpholino and 
uninjected controls. We scored 48 hpf embryos by designating the progenitor expression pattern 
as small, normal, or large. Knockdown of three genes, pnpla3, mapk10, and pklr using ATG-site 
morpholinos led to diminished hhex expression (Figure 3-2, B, D, F) with corresponding 
significant increases in the proportion of small progenitor populations within the cohort of 
injected embryos (Figure 3-2, A, C, E, n=42-103, Chi-squared test, p < 0.05). We found 
concordant results when using both ATG and splice-site morpholinos (Table S3-2, in appendix). 
These findings indicate that genes found to be associated with markers of liver injury in adults 
can play a role in the earliest phases of liver specification and growth.  
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Figure 3-2 (next page). Effect of gene knockdown on hepatic progenitor population. 
Knockdown of pnpla3, mapk10, and pklr using ATG-site morpholinos decreased the proportion 
of embryos with small progenitor population in a statistically significant manner (A, C, E), as 
evidenced by in situ hybridization for hhex expression at 48 hpf (B, D, F).  
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Figure 3-2 (continued) 
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Knockdown of gene candidates impacts liver size and hepatocyte gene expression 
In order to determine whether the 14 gene candidates affect liver differentiation and 
growth, we also examined fabp10a expression at 72 hpf, which is a marker of differentiated 
hepatocytes. Knockdown of pnpla3, mapk10, and pklr using ATG site morpholinos resulted in an 
increase of smaller livers and smaller hepatic progenitor population in the injected embryos 
compared to controls (Figure 3-3, A-F, n=29-173, Chi-squared test, p < 0.05).  These observed 
effects could be the result of diminished hepatic progenitor numbers, or due to impaired 
hepatocyte differentiation and growth. In contrast, a greater number of candidate genes altered 
fabp10a expression at 72 hpf compared to hhex at 48 hpf: knockdown of cpn1, trib1, fads2, 
slc2a2, samm50 all resulted in diminished fabp10a expression in a greater proportion of smaller 
livers compared to controls (Figure 3-3, G-P, n=29-173, p < 0.05). We found similar results 
when using both ATG and splice-site morpholinos (Table S3-3, in appendix). Five of the gene 
candidates tested exhibited no difference in both hhex or fabp10a expression after morpholino-
knockdown (mif, aldob, efna1a, efna1b, and mical3, not shown). These results reveal that our 
selection process identified a group of gene candidates important for proper function and 
development of differentiated hepatocytes (Table 3-4).  
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Figure 3-3 (next page). Effect of gene knockdown on hepatocyte gene expression and liver size. 
Knockdown of 8/14 genes (pnpla3, trib1, slc2a2, mapk10, cpn1, fads2, pklr, and samm50) by 
ATG-site morpholino injection decreased the proportion of embryos with small progenitor 
population in a statistically significant manner (A, C, E, G, I, K, M, O), as evidenced by in situ 
hybridization for fabp10a expression at 72 hpf (B, D, F, H, J, L, N, P).  
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Figure 3-3 (continued) 
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Figure 3-3 (continued) 
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Table 3-4: Summary of liver phenotypes after ATG morpholino-knockdown of 14 zebrafish 
candidate genes 
Gene knockdown hhex expression 
fabp10a 
expression 
+2% EtOH   
(Oil Red O) 
+2.5 mM APAP 
(fabp10a expression) 
pnpla3 small small unchanged reduced 
cpn1 normal small unchanged N/A 
trib1 normal small unchanged reduced 
fads2 normal small unchanged N/A 
mif normal normal unchanged N/A 
slc2a2 normal small unchanged N/A 
pklr small small unchanged unchanged 
mapk10 small small unchanged unchanged 
aldob normal normal unchanged unchanged 
efna1a normal normal unchanged N/A 
efna1b normal normal unchanged N/A 
samm50 normal small unchanged reduced 
mical3a normal normal unchanged unchanged 
mical3b normal normal unchanged unchanged 
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Knockdown of gene candidates does not alter susceptibility to liver injury 
In order to demonstrate the relevance of the developmental phenotypes for organ 
homeostasis, we next examined if morphant embryos show altered susceptibility to previously 
established models of liver injury in zebrafish embryos (North et al., 2010; Passeri et al., 2009). 
Exposure of 96 hpf embryos to 2% ethanol for 32 hours leads to increased neutral lipid 
accumulation in the liver in 50-60% of embryos as assayed by whole mount Oil Red O staining, 
indicative of alcoholic steatosis (Passeri et al., 2009). Morpholino knockdown of the candidate 
genes did not alter the susceptibility of zebrafish larvae to fatty liver following ethanol exposure 
when compared to uninjected or standard morpholino-injected siblings (Figure 3-4, A-B). These 
results indicate that loss of function of the selected candidate genes does not impair the 
predisposition of the embryos to respond to metabolic stress and develop hepatic steatosis. 
We next investigated susceptibility to toxic liver injury in a subset of gene candidates, 
making use of a previously developed acetaminophen (APAP) larval injury model (North et al., 
2010). Exposure of 48 hpf embryos to 5 mM acetaminophen (APAP) until 96 hpf causes liver 
damage with smaller livers and diminished survival in the majority of embryos. We exposed 
morphant embryos to a lower concentration of APAP (2.5 mM) to decrease the proportion of 
small, damaged livers and therefore more easily observe altered susceptibility. APAP treatment 
of pnpla3, samm50, and trib1 morphants resulted in a greater proportion of small livers 
compared to APAP treatment of controls (Figure 3-4, C-D, n=41-290, Fisher’s exact test for 
paired controls, p < 0.05), whereas exposure of pklr, mapk10, and aldob morphants to APAP did 
not alter the proportion of damaged livers. We observed corresponding results when using splice-
site morpholinos (Table S3-4, in appendix). However, while morphants generated using the 
samm50 splice site morpholino and then exposed to APAP had reduced fabp10a expression 
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compared to controls, this was not statistically significant. This could be explained by decreased 
efficacy of the splice-site morpholino compared to the ATG at equal doses. Importantly, the 
overall observation, i.e. increased susceptibility to APAP damage, between ATG and splice-site 
morpholino was consistent. These results indicate that the selected genes may be important for a 
differential response to drug-induced acute liver injury in this model (Table 3-4). 
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Figure 3-4 (next page). Impact of gene knockdown on hepatic injury after ethanol or APAP 
treatment. Treatment of zebrafish embryos with 2% ethanol from 96-128 hpf leads to fatty 
droplet formation in embryonic livers, as detected by whole mount Oil Red O staining (A). 
Injury induction in control and ATG-site morphant embryos resulted in no statistical difference 
in fatty liver incidence (B). Treatment of zebrafish embryos with 2.5 mM acetaminophen 
(APAP) from 48-96 hpf leads to small livers compared to untreated controls, as assessed by in 
situ hybridization for the hepatocyte marker fabp10a (C). Knockdown of pnpla3, samm50, and 
trib1, followed by treatment with 2.5 mM APAP increased the proportion of small livers 
compared to APAP treatment alone (D). 
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Figure 3-4 (continued) 
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Discussion 
 
GWAS have been applied to a wide variety of phenotypes, ranging from chronic and 
infectious diseases to cancer. However, in many instances, these studies have not provided 
functional and mechanistic insight into the candidate genes identified. Investigating the 
molecular significance and function of novel genes identified by GWAS can distinguish between 
the true biological mediators involved in human disease pathogenesis and genes that merely 
correlate with disease. Furthermore, biologically relevant GWAS results can reveal novel 
therapeutic targets for drug design. Unfortunately, many GWAS findings lack follow-up due to 
the sheer number of loci and genes identified or lack of preliminary data to warrant an in-depth 
investigation of individual gene candidates. Here, we present an in vivo candidate-gene approach 
to functionally validate a subset of genes identified by a GWAS for loci influencing plasma liver 
enzyme levels. We narrowed down a list of 69 GWAS candidate genes in 42 loci to 14 zebrafish 
genes based on available zebrafish orthologs, zebrafish and/or liver gene expression pattern, and 
known disease correlation. We knocked down each candidate gene in zebrafish embryos using 
morpholinos and assessed response to liver injury, development of hepatic progenitor 
populations, and development of differentiated hepatocytes. Our results revealed a range of 
phenotypes: some morphants had unaltered livers, but the majority of morphants (8/14) exhibited 
smaller livers at 72 hpf compared to controls, and a subset of those morphants demonstrated a 
smaller progenitor population and showed enhanced susceptibility to APAP-induced liver injury. 
All the morphants with a decreased hhex-expressing domain also showed decreased fabp10a 
expression, suggesting that a smaller number of liver progenitors impacted subsequent 
differentiation and growth of differentiated liver cells. Due to straight-forward imaging and 
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analytical methods and high fecundity, the zebrafish embryo represents a cost-effective method 
for rapidly assessing a list of candidate genes for their biological and functional importance. 
Interestingly, all genes associated with ALT concentrations resulted in smaller livers at 
72 hpf after knockdown, suggesting that liver homeostasis mechanisms present in the adult liver 
are also functional in the developing liver and may be important for hepatocyte differentiation or 
development itself. Furthermore, our approach revealed the opportunity to deconvolute separate 
functions of genes associated with a phenotype by the same sentinel single nucleotide 
polymorphism (SNP): we characterized two genes that are located in the same genomic region, 
associated with ALT concentrations by the same sentinel SNP rs738409, samm50 and pnpla3. 
These genes demonstrate a different phenotypic profile when knocked down during 
development: samm50 morphants only exhibit reduced fabp10a expression, whereas pnpla3 has 
diminished expression of both hhex and fabp10a. These results confirm that both genes in this 
locus have an important developmental requirement and may function independently at different 
stages of development. Remarkably, knockdown of pnpla3 and samm50 also enhanced 
susceptibility to APAP liver toxicity, as measured by reductions in fabp10a expression reflective 
of liver damage and apoptosis (North et al., 2010). This susceptibility, also found in trib1 
morphants, may be APAP specific, but may also be correlated to plasma liver enzyme elevation. 
For example, liver enzymes increase not only during APAP-induced liver toxicity but also in 
other types of metabolic or toxic liver injury, and enzyme levels can be further increased by 
APAP exposure (Aubert et al., 2012; Kučera et al., 2012; Majhi et al., 2011). These functional 
data may inform further genomic studies to identify differentiating SNPs between pnpla3 and 
samm50 that may correlate with gene function. 
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As with other global screening techniques, our approach may reveal false negative 
results: we cannot exclude an important biological function for a candidate gene even if 
knockdown resulted in no early liver phenotype. These genes may have redundant functions, a 
gain-of-function phenotype, or become active later in development or only in specific injury or 
disease states not tested here. For example, a specific PNPLA3 polymorphism in humans is 
associated with alcoholic and nonalcoholic liver disease (Romeo et al., 2008; Tian et al., 2009), 
and zebrafish pnpla3 morphants have altered susceptibility to acetaminophen but not ethanol-
induced liver injury. Recently, it has been confirmed that this PNPLA3 polymorphism confers an 
activating mutation (Li et al., 2012); therefore, studying zebrafish pnpla3 morphants may not be 
informative with regards to the steatosis phenotype, but can still be useful for studying liver 
development or additional models of liver injury. The lack of statistically significant results in 
the ethanol injury induction assays may result from the limitations of the injury itself, which may 
not adequately test for the correct pathway or developmental time point important for the 
function of our candidate genes. Furthermore, morpholino dilution in the older, 128 hpf embryos 
may also account for lack of difference in the ethanol model.  
However, for morphants that do exhibit a liver development phenotype, we can use this 
analysis as a launching point for additional in-depth studies into the molecular mechanisms and 
disease functions of these genes. Since these candidates were initially identified in an adult 
GWAS, we expected that more genes would impact differentiated hepatocytes rather than 
progenitors. Our assessment of hepatoblast and hepatocyte populations using in situ 
hybridization was semi-quantitative, enabling a rapid morphological assessment as a screening 
process. For those genes that are important for embryonic liver development, further quantitative 
and cellular analyses, such as quantitative RT-PCR for liver-specific genes, cell counts in liver-
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specific reporter lines, and histological analysis, including stains for cell proliferation or cell 
death, will be valuable tools to provide an in-depth characterization of the morphant phenotypes. 
Further work may aim to distinguish the roles of individual genes in hepatocyte differentiation, 
proliferation, or liver function. For example, TRIB1 has been implicated in the regulation of 
hepatic lipogenesis in humans, and trib1 morpholino knockdown results in reduced fabp10a 
expression in zebrafish and increased susceptibility to APAP-induced liver toxicity. 
Polymorphisms in TRIB1 are associated with an improved lipid profile and decreased risk of 
myocardial infarction in humans and Trib1 knockout mice have elevated plasma triglyceride and 
cholesterol levels (Burkhardt et al., 2010). We can now speculate that trib1 may also have a role 
in liver development that only impacts hepatocytes since lipid metabolism may be more 
important in functional, differentiated liver cells, and trib1 gene knockdown leading to elevated 
lipid levels may disrupt normal cell growth and proliferation, while the zebrafish embryo is still 
utilizing yolk as a primary source of energy. Another gene of interest is mapk10, which unlike 
trib1, seems to impact all stages of liver development and not only the hepatocytes when 
knocked down. Genetic and epigenetic alterations in human MAPK10 have been implicated in 
cancers such as lymphomas and lung and liver carcinomas (Kim et al., 2005; Ying et al., 2006). 
Although MAPK10 is primarily known as a pro-apoptotic factor, MAP kinase family proteins are 
involved in a variety of cell fate processes integral to the developing embryo and its disruption 
during early development may prevent the proper cell fate decision-making steps to specify and 
propagate the entire hepatic lineage.  
The data presented here can identify genes for zebrafish knockout studies or experiments 
in mammalian systems. Zebrafish TILLING mutants have been identified for a handful of 
GWAS candidate genes, and genome editing methods such as transcription activator-like effector 
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nucleases (TALEN) now provide a feasible way for the zebrafish community to generate 
complete genetic knockouts (Bedell et al., 2012; Huang et al., 2011; Sander et al., 2011). 
Zebrafish mutants can be used to investigate larval and adult phenotypes and perform additional 
liver injury or disease-induction experiments to further elucidate the roles of GWAS candidate 
genes during normal liver physiology and disease. 
Zebrafish embryos have previously been used as a tool for rapidly confirming and 
examining GWAS results in multiple organ systems such as the kidney, bone and the 
hematopoietic system (Gieger et al., 2011; Liu et al., 2011; Pattaro et al., 2012; Xiao et al., 2012). 
Here, we show that GWAS results providing a long list of gene candidates can be prioritized to 
characterize a feasible number of candidates for biological validation in zebrafish. We focused 
on 14 candidate zebrafish genes for morpholino-knockdown selected from an original list of 69 
human genes associated with plasma liver enzyme concentrations, based on data from public 
databases and published literature. Of these 14 candidates, we identified 8 zebrafish genes 
required for normal embryonic liver development, three of which are also required for the 
normal specification of hepatic progenitors. We anticipate that these results will lead to more 
comprehensive analyses of individual candidate genes and their roles in liver homeostasis. 
Furthermore, our approach demonstrates the feasibility of utilizing large gene lists generated by 
GWAS for a more focused functional analysis of candidate genes. As annotation of the zebrafish 
genome improves and more expression data becomes available, a greater number of zebrafish 
orthologs from GWAS can be assessed. We expect that zebrafish will be widely utilized to 
confirm data from GWAS for divergent phenotypes with developmental or disease implications. 
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Materials and Methods 
 
Morpholino injection 
 
Morpholino oligonucleotides (GeneTools, LLC, Philomath, OR) were designed against 
the ATG start site and splice sites of 14 zebrafish genes (Tables 3-2 and 3-3). Primers were 
designed to sequence the morpholino target site of the ATG morpholinos in AB and Tubingen 
zebrafish strains to verify absence of SNPs in this region (S3-1). Each morpholino was injected 
into one-cell stage embryos, with uninjected embryos and embryos injected with a standard 
morpholino acting as controls. Injections were performed with an initial morpholino 
concentration of 50 µM and increased for those morpholinos that initially caused no liver 
phenotype. 
In situ hybridization 
 
In situ hybridization was conducted on embryos fixed in paraformaldehyde using 
standard protocols (http://zfin.org/ZFIN/Methods/ThisseProtocol.html) and RNA probes for 
hematopoietically-expressed homeobox protein (hhex) and liver fatty acid binding protein 
(fabp10a) were used to visualize the hepatic progenitor and hepatocyte cell populations, 
respectively. hhex or fabp10a expression changes were assessed by scoring the expression 
pattern in control embryos as “small,” “normal,” and “large” within a population distribution, 
and compared to the size distribution of the hhex or fabp10a-expressing field in morphant 
embryos. The percentage altered of the total population was then calculated for each morphant 
group. Chi-squared test and Fisher’s exact test were used to compare changes in the scored 
populations. 
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Oil Red O staining 
 
 Whole mount Oil Red O staining of embryos was conducted as previously described 
(Passeri et al., 2009). Control and morphant embryos at 96 hpf were fixed in paraformaldehyde, 
washed with PBS and increasing concentrations of propylene glycol in PBS, and stained 
overnight with 0.5% Oil Red O in propylene glycol. After staining for 32 hours, embryos were 
washed with decreasing concentrations of propylene glycol and PBS. Embryos were scored 
based on presence of lipid droplets in the liver. 
 
Translational Impact  
 
Clinical Issue: Genome-wide association studies (GWAS) examine the relationship 
between gene variants and human traits, including markers of disease. Many new relationships 
have been uncovered using GWAS, but the confirmation and analysis of how these gene variants 
contribute to normal biology and disease is lacking. A recent GWAS uncovered 69 gene 
candidates at 42 loci associated with high levels of plasma liver enzymes, which is a marker of 
liver injury. Liver enzyme concentrations are used to diagnose and monitor diseases such as 
alcoholic and non-alcoholic fatty liver disease, hepatitis, cirrhosis, and drug-induced liver injury. 
The function of most of these candidate genes in liver homeostasis is unknown and methods to 
prioritize the genes most important to liver biology are insufficient. Determining the function of 
these candidates in liver biology can inform the development of new liver disease treatments. 
Results: This study used zebrafish to examine the GWAS candidates that may have the 
greatest impact on normal liver development and function. Zebrafish give rise to hundreds of 
progeny at one time and zebrafish embryonic development proceeds more quickly than 
mammalian development, thus making this model organism an advantageous tool to rapidly 
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study multiple gene candidates. The authors first identified the 43 genes from the GWAS with 
zebrafish orthologs, and used public databases and literature to identify 12 genes most likely to 
have liver or metabolic disease correlation, but no known role in liver development. We knocked 
down these genes during zebrafish development and found that three gene candidates were 
necessary for liver progenitor formation, and 5 additional gene candidates were determined to be 
necessary for liver growth and maturation. We also found that knockdown of three gene 
candidates resulted in the embryos’ enhanced susceptibility to toxic liver injury.  
Implications and Future Directions: The data demonstrate that using zebrafish to assess 
knockdown of GWAS gene candidates that influence liver enzyme levels can be an effective way 
to prioritize genes for further study. The authors identified eight GWAS candidates that also 
have a role in liver development and injury, implying that factors influencing liver homeostasis 
in adult humans can also be important for liver maturation. Future work includes exploring the 
molecular mechanisms and disease functions of these genes in greater detail using zebrafish and 
mammalian models, mutants, and additional cellular, molecular, and physiological tools. This 
method to rapidly validate GWAS results can be applied to additional GWAS for other disease-
associated traits. 
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Chapter 4: Discussion 
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Summary 
 
Nonalcoholic and alcoholic fatty liver diseases are characterized by fat accumulation in 
hepatocytes; however, continuous fat deposition leads to steatohepatitis and irreversible cirrhosis. 
These conditions are significant health concerns due to lack of treatment options and a limited 
understanding of disease mechanisms and associated morbidity and mortality. Liver disease 
pathogenesis involves not only environmental factors but also genetic and regulatory aberrations 
that affect embryogenesis and organogenesis. Studying novel regulators in liver development can 
shed light on important liver homeostatic processes that are disrupted during liver injury or 
chronic disease. In vertebrates, the liver is specified from the endoderm germ layer during 
embryogenesis. This process is conserved in zebrafish, which we use as a valuable model 
organism to study developmental processes and disease induction in a high-throughput manner. 
Zebrafish develop rapidly and externally compared to mammalian models, display remarkable 
fecundity, and model liver disease that can be modulated by genetic or chemical manipulation.  
One approach to investigating chronic liver disease is to study novel pathways during 
development, followed by comparison to a similar human injury state. In Chapter 2, we 
discussed the role of the endocannabinoid (EC) signaling pathway, which has been previously 
implicated in animal models of chronic liver disease. The CB1 and CB2 receptors are expressed 
in the central nervous system, but also have independent effects on peripheral tissues such as the 
endoderm-derived gut and liver. These receptors have opposing roles during hepatic lipogenesis 
and fibrogenesis. Before the development of genome-editing nucleases such as TALENs or the 
CRISPR-Cas9 system, the zebrafish community lacked methods to generate targeted knockouts. 
This work is one of the first examples of zebrafish mutants generated solely for extensive 
phenotypic analysis and disease modeling. Using cnr1-/- and cnr2-/- mutants, we show that EC 
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signaling through CB1 and CB2 in the developing zebrafish embryo is required for normal 
maturation and function of hepatocytes, but not earlier milestones such as hepatic specification. 
We also provide evidence that methionine metabolism is an integral mediator in this process. 
This work gives strong evidence for either a developmental defect or an underlying metabolic 
abnormality that impacts adult liver homeostasis. 
Another way to study regulators of liver development that become dysregulated during 
disease is to begin with a human data set of genes with potential disease associations, but may 
have unknown biological functions. Genome-wide association studies (GWAS) uncover many 
novel relationships, but analysis of how gene variants contribute to normal biology or disease 
pathogenesis is lacking. In Chapter 3, we applied a GWAS data set for elevated plasma liver 
enzymes, which are used to monitor liver disease progression, to show that zebrafish are an 
effective in vivo validation system for assessing a panel of genes with conserved roles in 
development and disease. We analyzed public databases and published literature to reduce 69 
GWAS candidates to 13 zebrafish genes for assessment by morpholino knockdown. We 
examined morphant and control embryos for differences in susceptibility to metabolic and toxic 
injury as well the development of hepatic progenitor and hepatocyte populations. This approach 
can be applied to GWAS data sets for other traits that can be studied in a zebrafish 
developmental context.  
Future Directions and Conclusions 
 
The results in Chapter 2 provide intriguing insight into developmental energetics that has 
not been extensively studied. Initially, we sought to determine the role of EC signaling in 
hepatocyte differentiation and proliferation; however, we also realized the significance of this 
pathway for hepatic physiology and metabolism during embryo and larval stages, with defects 
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sustained into adulthood in cannabinoid receptor mutants. The metabolic requirements of the 
developing embryo have not been well characterized and how nutritional demands inform 
organogenesis is still an ongoing area of research.  
In zebrafish, the transition from an embryo’s dependence on yolk lipids to requiring food 
involves the confluence of several developmental and physiological milestones: the maturation 
and function of digestive system organs, activation of CNS and peripherally derived appetite 
signals, and contribution of gut microbiota. These processes have similar parallels to mammalian 
developmental stages in utero and postnatally, and current research has mostly assessed how in 
utero nutrition can impact adult health, with an emphasis on epigenetic regulation. Accordingly, 
our work found that disrupting a pathway important for appetite regulation, liver development, 
and EC signaling also impacted methionine metabolism, which is best known to generate methyl 
groups for cellular methylation processes such as DNA and protein methylation that are 
important for gene expression and regulation. Correlations between diet and environmental 
exposure leading to long term metabolic dysregulation have been established in mammals, and 
maternal diet can impact DNA methylation in offspring (Ozanne, 2014). Specifically, reducing 
methionine in the mammalian diet disrupts proper DNA methylation and leads to increased 
adiposity (Sinclair et al., 2007), and similarly, lack of proper nutrition in the embryo can lead to 
DNA methylation defects and aberrant adult metabolism (Radford et al., 2014).  
In addition to our findings in the context of hepatogenesis, we provide new insights into 
different aspects of the metabolic syndrome including obesity and hepatic steatosis, which are 
known to have a genetic component in addition to their environmental causes. A future area of 
research could determine the timing and magnitude of early genetic or drug interventions that 
may ameliorate progressive diseases in adulthood. This could utilize adult zebrafish models of 
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liver disease and inducible mammalian models. Further work may also include dissecting the 
specific metabolic intermediates responsible for the observed effects through metabolic tracing 
of isotope-labeled nutrients. Additionally, cell lineage tracing at embryonic and larval stages can 
ascertain the specific cell populations involved, including inflammatory and immune cells not 
present until later developmental stages in zebrafish. We plan to conduct RNA sequencing 
analysis on cannabinoid receptor mutants compared to wild type animals at multiple stages of 
development. Comparison to polar metabolomics data can reveal metabolic derangements in 
other pathways, or dysregulation of metabolic enzymes. RNA sequencing can also reveal 
differential gene expression patterns in embryos compared to adults that could reveal how 
organisms grow and adapt to metabolic demands. Furthermore, dysregulation of novel pathways 
that have no previous association with liver development or metabolism can provide clues for 
additional functions of EC signaling or points of therapeutic intervention.  
The work shown in Chapter 3 used morpholino injection to rapidly assess multiple genes 
for biological significance.  Since then, advances in the genome editing field have resulted in 
cheaper and faster molecular biology methods to apply this technology to in vitro experiments 
and animal models alike. The efficiency of the CRISPR-Cas9 system has increased such that 
phenotypes can even be screened in mosaic embryos. In future studies, instead of employing 
morpholinos to assess a panel of genes, injection of CRISPR-Cas9 constructs may be used to 
screen for biological significance in newly injected embryos, which can be grown to adulthood 
and outcrossed to generate germline mutants. In some cases, morpholinos have failed to replicate 
a mutant phenotype (or lack of phenotype) seen in germline mutants (Kok et al., 2015), and the 
future of zebrafish research may increasingly require confirmation of phenotypes in both mutants 
and morphants.  
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Much can be gleaned from conducting screens in zebrafish. The same chemical screen 
that identified cannabinoid agonists as potential modifiers of liver growth also identified 
additional pathways involved in liver development and pathogenesis. The cannabinoid receptors 
were found not only to be necessary for proper liver maturation, but also for response to alcohol 
and nutritional-induced liver injury and as an upstream regulator of methionine metabolism. 
Retinoic acid, another pathway discovered by this screen, was found to be important for 
regulating organ laterality, while prostaglandin E2 was found to modulate the hepato-pancreas 
cell fate decision, and nitric oxide signaling was found to modify acetaminophen-induced liver 
toxicity (Cox et al., 2013; Garnaas et al., 2012; Nissim et al., 2014). These pathways were 
identified using the same phenotypic output, but their biological functions in liver development 
and liver disease proved to be diverse. The first zebrafish screens assayed mutations in early 
development that resulted in easily identifiable phenotypes. This particular chemical screen 
incorporated a fluorescent reporter to isolate a specific biological phenomenon. In the near future, 
variations of chemical and genetic screening may include different chemical libraries, 
automation, and high throughput imaging tools to survey more complex phenotypes and 
developmental time points.  
Information from screens, human GWAS data sets, or other high throughput or candidate 
gene approaches can be starting points for taking advantage of the zebrafish model in 
developmental biology and translational research. New developments in the genome editing 
community are quickly being adapted to zebrafish: not only can researchers create loss of 
function mutations, the next frontier in genome editing includes conditional mutations, gain of 
function mutations, and altering gene regulation (Bedell et al., 2013; Gagnon et al., 2014; 
Konermann et al., 2015; Yang et al., 2013). Making observations during zebrafish development 
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has progressed from simple light microscopy to confocal imaging, electron microscopy, and light 
sheet microscopy to view biological phenomena at increasing magnification and resolution. New 
advances in constructing fluorescent reporters for lineage tracing, and ingestible/diffusible dyes 
allow for visualization of physiological processes in normal and aberrant states using live 
animals. All these techniques will prove useful as disease modeling in zebrafish continues to 
improve and manipulations are not solely restricted to the embryo but also include larval and 
adult stages. Studying these later developmental time points will inform interaction of multiple 
cell types and tissues, and the contributions of the immune system and inflammatory response 
that is not yet mature in the embryo.  
 These recent and ongoing advances will shed light on the genetic factors involved at the 
intersection of development and disease progression. One area of critical need in the liver disease 
field is generating improved models of liver fibrosis, which is ultimately the stage of chronic 
liver disease that destroys liver function. Mouse models of liver disease fail to recapitulate all 
features seen in humans, and the medical community still lacks therapeutic options that target 
fibrosis, restore normal hepatocyte function, and lessen the need for liver transplantation. A 
combination of improved zebrafish disease models, particularly in larval stages, and the 
development of rapid imaging or staining techniques in conjunction with a zebrafish screen for 
modulators of liver fibrosis could eventually lead to drug options and a better understanding of 
fibrosis induction and resolution. 
The ultimate goal of this research is to use a combination of molecular and cellular 
techniques, along with animal modeling and human data to gain therapeutic insight for early 
interventions that may minimize adult disease phenotypes. EC signaling is only one of many 
pathways that function in both liver development and as a modulator of liver disease. Similarly, 
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elevated plasma enzyme levels are only one class of traits that are associated with liver disease 
progression and severity. Understanding these and related pathways, including not-yet defined 
regulators and how they collaborate to direct organ formation and homeostasis is key to 
determining the underlying molecular contributions to disease.  
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Appendices 
 
Appendix 1: Chapter 2 Supplemental Data 
 
Figure S2-1 (next page). Cannabinoid receptor expression in the developing zebrafish 
!In situ hybridization images at 24, 48, and 72 hpf showing that cnr1 and cnr2 are expressed in 
the developing central nervous system, endoderm, and liver regions. Scale bar = 0.2 mm.  
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Figure S2-1 (continued) 
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Figure S2-2 (next page). Generation of cannabinoid receptor mutants  
A) Wild-type and mutant sequence of the TALEN target region in the cnr1 and cnr2 genes.  
B) The small deletions shown in the DNA sequence lead to translation of an early stop codon in 
the first exon of both cnr1 and cnr2.  
C) Box plot based on liver morphometric measurements using ImageJ showing normal liver size 
of cnr1+/- and cnr2+/- zebrafish at 72 hpf.  
D) Morpholino knockdown of cnr1 or cnr2 in Tg(fabp10a:GFP) reporter fish leads to smaller 
livers at 72 hpf. Scale bar = 0.2 mm.  
E) FACS quantification of Tg(fabp10a:GFP) embryos treated with cannabinoid agonists. % of 
GFP+ cells were normalized to controls.  
F) FACS quantification of Tg(fabp10a:GFP) embryos injected with cnr1 and cnr2 morpholinos. 
Morphants embryos at 72 hpf show an increased number of GFP positive hepatocytes at 72 hpf 
with agonist treatment and decreased number of GFP positive cells when cnr1 and cnr2 are 
knocked down.  
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Figure S2-2 (continued) 
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Figure S2-3 (next page). Liver phenotypes in cnr1 and cnr2 morphants 
 
!A) Box plot and representative in situ hybridization images showing liver size of cnr1-/- and cnr2-
/- mutants at 96 hpf and  
B) 120 hpf based on liver morphometric measurements using ImageJ. At 96 hpf, livers in cnr1-/- 
and cnr2-/- mutants are still significantly smaller than control, but this difference disappears by 
120 hpf. Data are represented as mean ± SEM with one-way ANOVA analysis, n > 20 samples, 
*p<0.05 for Tu compared to and at 96 hpf only. Scale bar = 0.2 mm.  
C) 120 hpf transverse sections stained for the PCNA antibody and counterstained with methyl 
green show decreased number of PCNA-positive cells in the cannabinoid receptor mutants 
compared to control. Scale bar = 0.1 mm.  
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Figure S2-2 (continued) 
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Figure S2-4 (next page). Conservation of metabolic phenotypes in zebrafish cannabinoid 
receptor mutants ! 
A) After inducing liver injury with ethanol, cnr1-/- but not cnr2-/- mutants at 120 hpf are protected 
from acquiring fatty liver as assessed by Oil Red O staining.  
B) Comparisons were made using Fisher’s Exact test on >30 samples, ***p<0.001 compared to 
control treatment. Scale bar = 0.2 mm.  
C) cnr1-/- mutants have decreased hepatic stellate cell activation in the ethanol-induced liver 
injury model based on hand2 expression in the liver by in situ hybridization  
D) Fisher’s Exact test, n >30, **p<0.01. Scale bar = 0.2 mm.  
E) Co-treatment with cannabinoid agonists and antagonists reveal that CB1/2 agonist increases 
steatosis incidence in the ethanol-induced liver injury model while the CB1 antagonist and CB2 
agonist prevents steatosis induction. Fisher’s Exact test, n >30, **p<0.01 and ***p<0.001.  
F) cnr1 but not cnr2 morphants are protected from induction of steatosis in the ethanol-induced 
liver injury model. Fisher’s Exact test, n >30, **p<0.01.  
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Figure S2-4 (continued) 
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Figure S2-5 (next page). cnr1 morphants and treatment with CB1 antagonist protects from 
hepatic steatosis and hand2 induction 
!A) cnr1-/- but not cnr2-/-mutants fed a high fat egg yolk diet from 96-120 hpf are also protected 
from fatty liver, as indicated by Oil Red O staining. 
B) Fisher’s Exact test, n >30 samples, **p<0.01 vs. controls. Scale bar = 0.2 mm.  
C) Co-treatment with cannabinoid agonists and antagonists reveal that CB1 antagonist and CB2 
agonist prevents steatosis induction in a high fat diet egg yolk feeding model. Fisher’s Exact test, 
n >30, *p<0.05 and ***p<0.001 vs. controls.  
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Figure S2-5 (continued) 
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Figure S2-6 (next page). Measurement of endocannabinoid content in cannabinoid receptor 
mutants  
A) Anandamide (AEA) and  
B) Arachidonylglycerol (1-AG and 2-AG) content in adult liver samples were measured by 
liquid chromatography/tandem mass spectrometry, revealing no statistically significant 
differences between control and mutant samples. Data are represented as mean ± SEM, n=2.  
C) Liver mass to body mass ratio measurements in female and D) male adult cnr1-/- and cnr2-/-
mutants show no difference in liver size between cannabinoid receptor mutants and controls by 
adulthood. 
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Figure S2-6 (continued) 
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Figure S2-7 (next page). Relative methionine metabolite levels after polar metabolomics 
analysis of adult livers 
!A) Heat maps show metabolites that are most dysregulated between wild type and cnr1-/- or cnr2-
/- mutants with p<0.05.  
B) Polar metabolomics analysis reveals relative levels of methionine pathway metabolites from 
male and  
C) female cnr1-/- or cnr2-/- adult livers. Data are represented as mean ± SEM, n=3. 
D) Box plot and  
E) representative in situ hybridization images at 72 hpf based on liver morphometric 
measurements showing reduced liver size of srebf2 morphants and failure of the CB1/2 agonist 
O2545, CB1 agonist L-HCl, and CB2 agonist JWH015 treatment from 24-72 hpf to rescue liver 
growth when srebf2 is knocked down. Data are represented as mean ± SEM with one-way 
ANOVA analysis, n > 20 samples, ****p<0.0001 for Tu compared srebf2 morpholino injection.  
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Figure S2-7 (continued) 
  
  133 
Table S2-1: qPCR primer sequences 
Gene Forward Primer Reverse Primer 
fabp10a GATGGAGGAAAGCTGGTCTG  TCCTGATCATGGTGGTTCCT  
ahcy ACCAGACAGCACAACGTCAA  AGACCCGGCATCTCATTCT  
mthfr GTCTGGAGCGGTCAATCTTATC  CGGGATGCCAAGTGATGT  
bhmt GCATGGAGTTACACCTGGAGA  CACAGTCTTCACACAGGTCAGG  
srm CGAAGTTCCAGGATGTGATG  GGTGGCAGCAGAGAGGTAGA  
srebf1 GTCTGTCGGCTTCACCAATC  GAGAGTCGGCCTTAATGAACTG  
srebf2 ACCATACAGACGCTCTCCACA     GGTTTGGTGGTCAGAAGCAG     
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Appendix 2: Chapter 2 Ongoing experiments 
 
 
 
Figure S2-8. Expression of additional hepatocyte markers in cnr1-/- and cnr2-/- mutants 
We assessed the expression of group-specific component (vitamin D binding protein) (gc), 
secreted immunoglobulin domain 4 (sid4), and transferrin (tfa), which are additional in situ 
hybridization markers for differentiated hepatocytes. We observed decreased expression of these 
markers in 72 hpf cnr1-/- and cnr2-/- mutants compared to control wild type embryos, confirming 
smaller liver size and excluding a dependence on fabp10a expression when cannabinoid 
receptors are knocked out in these mutants. 
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Figure S2-9. Hepatic progenitors remain unchanged in cnr1-/- and cnr2-/- mutants at 72 hpf 
We assessed the expression of hhex and prox1, which are in situ hybridization markers for 
hepatic progenitors. We observed no difference in expression pattern when comparing wild type 
and mutant embryos at 72 hpf. Along with the results in Figure S2-8, these data suggest that 
disruption of signaling through cannabinoid receptors impacts hepatic differentiation.   
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Figure S2-10. Knockdown of cnr1 and cnr2 impedes proper biliary tree formation 
We injected cnr1 or cnr2 morpholino in the Tg(notch:GFP) transgenic reporter, which expresses 
GFP in the biliary tree. At 96 hpf, we imaged the liver in morphant embryos by confocal 
microscopy and observed smaller liver size and decreased biliary branching and formation 
compared to control. Representative images are shown. 
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Figure S2-11 (next page). Investigating endocannabinoid signaling and cell autonomy 
We utilized a previously established system for driving morpholino knockdown exclusively in 
endodermally derived cell populations: sox32 is necessary and sufficient for endoderm formation 
in zebrafish, and overexpression of sox32 while co-injecting a morpholino of interest in 32-cell 
stage embryos restricts morpholino action to sox32-derived cell populations. When we co-
injected sox32 mRNA with cnr1 or cnr2 morpholino, we did not see any changes in liver size 
compared to control, suggesting that signals from outside the endoderm were responsible for the 
observed phenotypes. Subsequently, we conducted a similar experiment in the mesoderm using 
overexpression of the mesoderm marker ntl (Kristen Alexa, unpublished results); however, this 
also did not result in any changes in liver size. Therefore, it may be possible that signals from 
multiple germ layers are necessary for endocannabinoid action during liver development.  
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Figure S2-11 (continued) 
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Figure S2-12. Methionine treatment partially rescues the lipid processing defect in cnr2-/- 
mutants 
To determine if methionine treatment impacts the lipid deposition and decreased biliary 
branching seen in cnr2-/- mutants, we treated cnr2-/- mutants with methionine beginning at 24 hpf, 
followed by administration of BODIPY-C5 fluorophore at 6 dpf. We imaged the digestion of the 
C5 fatty acid molecule by confocal microscopy and observed that while there was extensive 
branching observed in wild type larvae, there was decreased branching with lipid and cholestatic 
deposition in the cnr2-/- mutants. However, the cnr2-/- mutants treated with methionine showed 
increased biliary branching and decreased fatty accumulation. These images suggest that 
methionine treatment beginning in early embryonic development may prevent the fatty 
phenotype observed in 6 dpf cnr2-/- mutants. Representative images are shown.  
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Figure S2-13. Methionine rescues liver development defect in ahcy morphants 
As a positive control, we assessed the role of methionine treatment in the context of a known 
methionine metabolism disruption.  Adenosylhomocysteine hydrolase (ahcy) is an essential 
enzyme in this pathway and functions to break down S-adenosylhomocysteine into adenosine 
and homocysteine. Mutants of this gene display hepatic steatosis and liver degeneration, 
followed by larval lethality (Matthews et al., 2009). Morpholino knockdown of ahcy resulted in 
smaller liver size at 72 hpf; however, treatment with methionine from 24-72 hpf rescued this 
liver size defect. This rescue indicates that methionine metabolism has a crucial role in the 
determination of liver size during hepatogenesis. 
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Figure S2-14. DNA methylation in cannabinoid receptor mutants 
We examined global DNA methylation levels by DNA slot blot. We extracted DNA from 72 hpf 
or 120 hpf cnr1-/- and cnr2-/- whole larvae or adult liver samples, and blotted for 5-
methylcytosine in samples with standardized DNA concentrations. This figure shows DNA slot 
blot of 5-methylcytosine expression in DNA samples from 72 hpf and 120 hpf whole zebrafish 
larvae, or adult zebrafish livers. There are no consistent differences in 5-methylcytosine 
expression in cnr1-/- and cnr2-/- mutant samples compared to controls. Methylene blue staining is 
shown at right as a loading control. Unlike western blotting, which separates a mixture of 
proteins on a gel and allows for visualization of multiple proteins that may be differentially 
affected by decreased methylation, the DNA slot blot technique may not be sensitive enough to 
distinguish among DNA methylation changes in specific genomic regions. 
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Figure S2-15. Methionine treatment does not rescue liver size in srebf1 and srebf2 morphants 
To establish an epistatic relationship between methionine metabolism and srebf1 and/or srebf2, 
we knocked down srebf1 and srebf2 using morpholinos and treated morphant embryos with 
methionine. Morphants exhibited smaller livers at 72 hpf, but methionine failed to impact liver 
size. Increasing methionine concentration up to 500 µM had no effect (data not shown). In this 
setting, transient knockdown using morpholino may not have been sufficient for studying the 
impact of methionine treatment or, alternatively, srebf1 and srebf2 may link to methionine 
metabolism via a feedback loop that cannot be rescued.  
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Figure S2-16. SREBP overexpression does not rescue lipid processing defects 
To determine if overexpression of srebf1 or srebf2 mRNA can rescue the aberrant lipid 
processing phenotypes observed in cnr2-/- larvae, we administered BODIPY-C5 fluorophore at 6 
dpf to cnr2-/- mutants alone or with srebf1 or srebf2 mRNA injection. We imaged liver 
morphology by confocal microscopy and did not observe major differences between cnr2-/- 
mutants and larvae with mRNA overexpression. One explanation for lack of rescue could be that 
mRNA overexpression at the one-cell stage is only transient and becomes diluted by 6 dpf. 
Alternatively, the defects caused by aberrant signaling through the CB2 receptor may be too 
severe for rescue by overexpression of a downstream regulator and an alternate pathway may be 
responsible for the observed effects.  
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Appendix 3: Chapter 3 Supplemental Data 
 
Table 3-2: ATG-site morpholinos designed to candidate genes 
Gene Target Sequence 
pnpla3 5’ TCCAGCCTTCCTTCAAATCAAACAT 3’ 
cpn1 5’ AGATGAGAGAGCTGCCTGACAGCAT 3’ 
trib1 5’ GGTTATGAATCCACTGCACGCTCAT 3’ 
fads2 
 
5’ TCCGCCACCCATCGCTGATCTCTGA 3’  
mif 5’ TTGTGTTCACTACAAACATCGGCAT 3’ 
slc2a2 5’ ACTGCTTCTCCATTTTGCATGAAGT 3’ 
pklr 5’ AGTAACGCCGGATACGAGCACCCAT 3’ 
mapk10 5’ ACGTCTGTTCATAAATACCTTGCAT 3’ 
aldob 5’ AGCAGCACACGGGATTAAAAGTGTA 3’ 
efna1a 5’ TGTATAAAAGCCACACCAGATCCAT 3’ 
efna1b 5’ CGCACAGCAGCCACAGAAAATCCAT 3’ 
samm50 5’ GTGTACGGTCCCCATGTTTAAAAGA 3’ 
mical3a 5’ CCGCATTGACGCCTCCATCTCCCAT 3’ 
mical3b 5’ TCTCAGACTGACCGTCCCACATCGC 3’ 
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Table 3-3: Splice-site morpholinos designed to candidate genes 
Gene Target Sequence 
pnpla3 5’ ATACATACAGTGGCATTACCTATGC 3’ 
cpn1 
 
5’ CTCCACTGAAAAACACAGGTCAGGT 3’ 
trib1 
 
5’ TATAGTATGCAGCGGTTTACCTTGC 3’ 
fads2 
 
5’ CCTTTAATATTTGACTCACCGTCTC 3’  
mif 5’ ATGTACTGTCACACAGACAAACACA 3’ 
slc2a2 5’ AACTGCTGCCAGACATGAAAACACA 3’ 
pklr 5’ GATACGAGCTGAATGATACACACAT  3’ 
mapk10 5’ ATCCACTGCAGGCAAAGAAGCATGA 3’ 
aldob 5’ GTGCCTAGAACATAAAACGGTCACA 3’ 
efna1a 5’ AAGTGCAACTCACAGATGTAGTAGT 3’ 
efna1b 5’ AGGCAAATTATGGACACTTACAGAT 3’ 
samm50 5’ TGACATTATGTCCATCTTACATCTT 3’ 
mical3a 5’ CCCAGGGAAACTTTCATACCTTAGT 3’ 
mical3b 5’ ACAACACAAGTGATACTTACCGTGC 3’ 
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Table S3-1: PCR primers for sequencing of ATG-site morpholino target region 
Gene Target Sequence 
pnpla3 
5’ CCGCAGCTGTATCCCTTCTA 3’,   
5’ GCATTACCTATGCAAGCCTCT 3’ 
cpn1 
5’ CAGCAATCATGCCTCAAAAA 3’, 
5’ GCCCTCACCATCTCCTCATA 3’ 
trib1 
5’ TTGCGTGAAATCAGACGGTA 3’, 
5’ ACTCTCAGCCAGGAAGGACA 3’ 
fads2 
5’ TTTGCTTTTGTGACCCAGTG 3’, 
5’ GCACCAAGCCAATGTTTCTA 3’ 
mif 
5’ GCGGGGTTTTACGGTAGTCT 3’, 
5’ GTGCTTACAGTTTTCTATCCCATCT 3’ 
slc2a2 
5’ AAGGTCTGATCCCAGCACAC 3’, 
5’ CTCCGGTCAATTTTGCAGTT 3’ 
pklr 
5’ AGCTTCAGGGAAGATGAGCA 3’, 
5’ TTTGGGAGAGGGATGATTTG 3’ and 
5’ TGCCTGAAGTCTTTTCTCTTATTTT 3’, 
5’ TCCAGCAGACACAGATGCTC 3’ 
mapk10 
5’ TGCCTTGTTGAGCGTAGTTG 3’, 
5’ CTAAGGAGGGGTTTGGGAAC 3’ and 
5’ CCTTCACGAACACCATCAGA 3’, 
5’ CTCACAGAATGGAAGTGAATGAA 3’ 
aldob 
5’ ATCGTTCAGTCCCGATTCAC 3’, 
5’ CACTTGCATGTTCACGGTTC 3’ 
efna1a 
5’ CGCGGATCTCTTGATTCAGT 3’, 
5’ CGAACACAGCGCAGATACTC 3’ 
efna1b 
5’ GCATTTAACCGCGTCTGTTT 3’, 
5’ CGCACACAGCTTGCATTAAG 3’ 
samm50 
5’ CAACGTGACGTGGTTGTTCT 3’, 
5’ GTTTCTGAACTCGGCCTGTC 3’ 
mical3a 
5’ TCATTCAGGGTGAAAATGTCC 3’, 
5’ AAGCCTTGAGAGTGCCTTTG 3’ 
mical3b 
5’ ATTGTCTGCTCCCCATTCAG 3’, 
5’ TTTCTGGCAGGCTCTTTTGT 3’ 
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Table S3-2: Effect of gene knockdown using splice site morpholinos on hepatic progenitor 
population (hhex expression).  
Morpholino % small % normal % large n Significance 
control 21.2% 73.7% 5.1% 99  
pnpla3 43.8% 56.3% 0.0% 112 p < 0.05 
      
control 18.1% 71.4% 10.5% 105  
cpn1 19.0% 71.4% 9.5% 84 n.s. 
      
control 14.3% 80.0% 5.7% 35  
trib 25.0% 65.0% 10.0% 40 n.s. 
      
control 10.2% 81.6% 8.2% 49  
fads2 16.0% 76.0% 8.0% 50 n.s. 
      
control 21.2% 61.5% 17.3% 52  
mif 24.1% 70.4% 5.6% 54 n.s. 
      
control 16.7% 72.9% 10.4% 48 . 
slc2a3 15.1% 77.4% 7.5% 53 n.s 
      
control 24.6% 69.2% 6.2% 65  
pklr 43.4% 55.8% 0.9% 113 p < 0.05 
      
control 12.3% 80.7% 7.0% 57  
mapk10 34.7% 61.3% 4.0% 75 p < 0.05 
      
control 19.2% 73.1% 7.7% 78  
aldob 29.5% 65.3% 5.3% 95 n.s. 
      
control 38.1% 61.9% 0.0% 21  
efna1a 48.1% 51.9% 0.0% 27 n.s. 
      
control 23.9% 71.7% 4.3% 46  
efna1b 32.1% 66.1% 1.8% 56 n.s. 
      
control 15.2% 74.2% 10.6% 66  
samm50 15.9% 76.2% 7.9% 63 n.s. 
      
control 18.5% 79.6% 1.9% 54  
mical3a 22.4% 74.1% 0.0% 58 n.s. 
      
control 25.0% 67.6% 7.4% 68  
mical3b 25.3% 65.9% 8.8% 91 n.s. 
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Table S3-3: Effect of gene knockdown using splice site morpholinos on hepatocyte gene 
expression and liver size (fabp10a expression).  
Morpholino % small % normal % large n Significance 
control 23.5% 70.6% 5.9% 34  
pnpla3 71.1% 26.3% 2.6% 38 p < 0.05 
      
control 35.6% 53.3% 11.1% 45  
cpn1 78.7% 21.3% 0.0% 47 p < 0.05 
      
control 36.4% 63.6% 0% 44  
trib 69.8% 30.2% 0% 53 p < 0.05 
      
control 18.2% 74.0% 7.8% 77  
fads2 43.7% 53.5% 2.8% 71 p < 0.05 
      
control 40.4% 51.1% 8.5% 47  
mif 31.0% 59.5% 9.5% 42 n.s. 
      
control 23.0% 67.0% 10.0% 100  
slc2a3 54.7% 35.9% 9.4% 117 p < 0.05 
      
control 26.2% 59.0% 14.8% 61  
pklr 67.2% 29.5% 3.3% 61 p < 0.05 
      
control 26.9% 73.1% 0.0% 26  
mapk10 87.5% 12.5% 0.0% 48 p < 0.05 
      
control 18.0% 72.1% 9.8% 61  
aldob 26.3% 63.2% 10.5% 57 n.s. 
      
control 20.0% 75.0% 5.0% 40  
efna1a 26.8% 68.3% 4.9% 41 n.s. 
      
control 30.4% 60.7% 8.9% 56  
efna1b 32.0% 60.0% 8.0% 50 n.s. 
      
control 8.6% 80.0% 11.4% 35  
samm50 65.4% 34.6% 0.0% 26 p < 0.05 
      
control 40.9% 54.5% 4.5% 44  
mical3a 42.9% 50.0% 7.1% 42 n.s. 
      
control 24.4% 63.3% 12.2% 90  
mical3b 32.6% 61.1% 6.3% 95 n.s. 
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Table S3-4: Susceptibility to metabolic and toxic injury after gene knockdown using splice-site 
morpholinos 
Gene knockdown +2% EtOH (Oil Red O) 
+2.5 mM APAP (fabp10a 
expression) 
pnpla3 unchanged reduced 
 
cpn1 unchanged unchanged 
 
trib1 unchanged reduced 
 
fads2 unchanged unchanged 
mif unchanged unchanged 
slc2a2 unchanged unchanged 
pklr unchanged unchanged 
mapk10 unchanged unchanged 
aldob unchanged unchanged 
efna1a unchanged unchanged 
efna1b unchanged unchanged 
samm50 unchanged Trend toward reduced 
mical3a unchanged unchanged 
mical3b unchanged unchanged 
 
 
 
 
